```
=> file registry
FILE 'REGISTRY' ENTERED AT 15:55:16 ON 14 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   13 MAR 2007  HIGHEST RN 926304-31-6
DICTIONARY FILE UPDATES:  13 MAR 2007  HIGHEST RN 926304-31-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> file caplus
FILE 'CAPLUS' ENTERED AT 15:55:19 ON 14 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 14 Mar 2007  VOL 146 ISS 12
FILE LAST UPDATED: 13 Mar 2007  (20070313/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html
'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> d stat que L25
L14          43 SEA FILE=CAPLUS ABB=ON  PLU=ON  ANGIBAUD P?/AU
L16        7835 SEA FILE=CAPLUS ABB=ON  PLU=ON  ?FARNESYL?/BI
L18       15726 SEA FILE=CAPLUS ABB=ON  PLU=ON  ?QUINAZOLIN?/BI
L19          11 SEA FILE=CAPLUS ABB=ON  PLU=ON  L14 AND L18
L20       69395 SEA FILE=CAPLUS ABB=ON  PLU=ON  ?TRIAZOL?/BI
L21          12 SEA FILE=CAPLUS ABB=ON  PLU=ON  L14 AND L20
```

```
L23          17 SEA FILE=CAPLUS ABB=ON  PLU=ON  L19 OR L21
L24          15 SEA FILE=CAPLUS ABB=ON  PLU=ON  L23 AND L16
L25          17 SEA FILE=CAPLUS ABB=ON  PLU=ON  (L23 OR L24)


=> d ibib abs hitind L25 1-17

L25  ANSWER 1 OF 17  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:        2006:101446  CAPLUS  Full-text
DOCUMENT NUMBER:         144:192266
TITLE:                   Preparation of substituted propenyl piperazine
                         derivatives as novel inhibitors of histone deacetylase
INVENTOR(S):             Van Brandt, Sven Franciscus Anna; Van Emelen, Kristof;
                         Angibaud, Patrick Rene; Marconnet-Decrane,
                         Laurence Francoise Bernadette; Arts, Janine
PATENT ASSIGNEE(S):      Janssen Pharmaceutica N.V., Belg.
SOURCE:                  PCT Int. Appl., 67 pp.
                         CODEN: PIXXD2
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    --------------------     --------
     WO 2006010749         A2    20060202    WO 2005-EP53611          20050725
     WO 2006010749         A3    20060608
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
             LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
             NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
             SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
             ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
             CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
             GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM
     CA 2572971            A1    20060202    CA 2005-2572971          20050725
PRIORITY APPLN. INFO.:                       EP 2004-77171        A   20040728
                                             US 2004-592357P      P   20040729
                                             WO 2005-EP53611      W   20050725
OTHER SOURCE(S):         MARPAT 144:192266
GI
```




I




II

AB Substituted propenyl piperazine derivs. I, wherein X is independently N or CH; R1 is Ph, naphthalenyl or heterocyclyl; wherein each of said Ph or naphthalenyl is optionally substituted with one or two substituents each independently selected from halo, alkyl, alkyloxy, poly-halo-alkyl, aryl, hydroxy, cyano, amino, alkylcarbonylamino, alkylsulfonylamino, hydroxycarbonyl, alkyloxycarbonyl, hydroxyalkyl, alkyloxymethyl, aminomethyl, alkylaminomethyl, alkylcarbonylaminomethyl, alkylsulfonylaminomethyl, aminosulfonyl, alkylaminosulfonyl or heterocyclyl; R2 is hydrogen, -CH2R5, trifluoromethyl, -C(O)-R6, or -CH-NR7R8; wherein each R5 is independently hydrogen, hydroxy, alkyloxy, alkyloxyalkyloxy, alkylcarbonyloxy, piperazinyl, N-methylpiperazinyl, morpholinyl, thiomorpholinyl, imidazolyl or ***triazolyl***; each R6 is independently hydroxy, alkyloxy, amino or mono- or di(alkyl)amino, cycloalkylamino, hydroxyalkylamino, piperazinyl, N-methylpiperazinyl, morpholinyl or thiomorpholinyl; each R7 and R8 are independently hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, or mono- or di(alkyl)aminosulfonyl; R3 is hydrogen, hydroxymethyl, aminomethyl or mono- or di(alkyl)aminomethyl; R4 is hydrogen or alkyl; were prepared and having histone deacetylase inhibiting enzymic activity and to inhibit proliferative conditions, such as cancer and psoriasis. Thus, propenyl piperazine derivative II was prepared and tested in vitro and in nude mice as inhibitor of histone deacetylase and was better than R306465 after oral administration. P21 enzyme linked immunosorbent assay has been applied to determine the p21 protein expression level in human A2780 ovarian carcinoma cells. In vitro assay for inhibition of histone deacetylase is reported. P21 induction was measured as the consequence of DNA damage or as the consequence of histone deacetylase inhibition. Antiproliferative activity of title compds. was determined on A2780 cells (neg. log value of the IC50, pIC50 = 7.9-8.2).

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 7, 63

L25 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:928872 CAPLUS Full-text
DOCUMENT NUMBER: 140:146059
TITLE: Substituted azoloquinolines and -***quinazolines*** as new potent ***farnesyl*** protein transferase inhibitors
AUTHOR(S): ***Angibaud, Patrick***; Bourdrez, Xavier; End, David W.; Freyne, Eddy; Janicot, Michel; Lezouret, Patricia; Ligny, Yannick; Mannens, Geert; Damsch, Siegrid; Mevellec, Laurence; Meyer, Christophe; Muller, Philippe; Pilatte, Isabelle; Poncelet, Virginie; Roux, Bruno; Smets, Gerda; Van Dun, Jacky; Van Remoortere, Pieter; Venet, Marc; Wouters, Walter
CORPORATE SOURCE: Medicinal Chemistry Department Johnson & Johnson Pharmaceutical Research & Development (J&JPRD), Campus de Maigremont BP615, Val de Reuil, 27106, Fr.
SOURCE: Bioorganic & Medicinal Chemistry Letters (2003), 13(24), 4365-4369
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 140:146059

AB A series of (4-chlorophenyl)-α-(1-methyl-1H-imidazol-5- yl)azoloquinolines and -***quinazolines*** was prepared These compds. displayed potent ***farnesyl*** protein transferase inhibitory activity and tetrazolo[1,5-a]***quinazolines*** are promising agents for oral in vivo inhibition.

CC 28-9 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1

ST *farnesyl* protein transferase inhibitor azoloquinoline *azoloquinazoline* prepn

IT 131384-38-8, *Farnesyl* protein transferase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of azoloquinolines and -*quinazolines* as *farnesyl* protein transferase inhibitors)

IT 192185-72-1, Zarnestra
RL: PAC (Pharmacological activity); BIOL (Biological study)
(preparation of azoloquinolines and -*quinazolines* as *farnesyl* protein transferase inhibitors)

IT 280144-91-4P
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
(preparation of azoloquinolines and -*quinazolines* as *farnesyl* protein transferase inhibitors)

IT 280143-75-1P 280143-77-3P 382146-82-9P 382146-83-0P
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of azoloquinolines and -*quinazolines* as *farnesyl* protein transferase inhibitors)

IT 280143-59-1P 280143-86-4P 280143-98-8P 280144-16-3P 280144-90-3P 280144-90-3P 280144-99-2P 652131-07-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of azoloquinolines and -*quinazolines* as *farnesyl* protein transferase inhibitors)

IT 67-64-1, Acetone, reactions 78-39-7, 1,1,1-Triethoxyethane 616-47-7, 1-Methylimidazole 624-84-0, Hydrazinecarboxaldehyde 1663-61-2, Triethoxymethylbenzene 22483-09-6, Aminoacetaldehyde dimethylacetal 192187-40-9 215034-82-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of azoloquinolines and -*quinazolines* as *farnesyl* protein transferase inhibitors)

IT 190898-78-3P 192187-32-9P 280143-17-1P 280143-18-2P 280143-19-3P 280143-20-6P 280143-21-7P 280143-22-8P 280143-27-3P 280143-38-6P 280143-48-8P 280143-53-5P 280143-54-6P 280143-79-5P 280143-80-8P 280144-85-6P 280144-89-0P 280144-98-1P 405548-67-6P 652131-05-0P 652131-06-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of azoloquinolines and -*quinazolines* as *farnesyl* protein transferase inhibitors)

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:928871 CAPLUS Full-text

DOCUMENT NUMBER: 140:156729

TITLE: 4-Methyl-1,2,4-*triazol*-3-yl heterocycle as an alternative to the 1-methylimidazol-5-yl moiety in the *Farnesyltransferase* inhibitor Zarnestra

AUTHOR(S): *Angibaud, Patrick*; Saha, Ashis K.; Bourdrez, Xavier; End, David W.; Freyne, Eddy; Lezouret, Patricia; Mannens, Geert; Mevellec, Laurence; Meyer, Christophe; Pilatte, Isabelle; Poncelet, Virginie; Roux, Bruno; Smets, Gerda; Van Dun, Jacky; Venet, Marc; Wouters, Walter

CORPORATE SOURCE: Medicinal Chemistry Department Johnson & Johnson

Pharmaceutical Research & Development (J&JPRD), Val de Reuil, 27106, Fr.
SOURCE: Bioorganic & Medicinal Chemistry Letters (2003), 13(24), 4361-4364
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 140:156729

AB Replacement of the 1-methylimidazol-5-yl moiety in the ***farnesyltransferase*** inhibitor Zarnestra series by a 4-methyl-1,2,4-***triazol***-3-yl group gave us compds. with similar structure-activity relationship profiles showing that this ***triazole*** is potentially a good surrogate to imidazole for ***farnesyltransferase*** inhibition.

CC 1-3 (Pharmacology)
Section cross-reference(s): 28

ST ***farnesyltransferase*** inhibitor Zarnestra quinolinone imidazole deriv prepn structure activity

IT Structure-activity relationship
(preparation and structure-activity relationship of quinolinone derivs. as ***farnesyltransferase*** inhibitors)

IT 131384-38-8, Protein ***farnesyltransferase***
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation and structure-activity relationship of quinolinone derivs. as ***farnesyltransferase*** inhibitors)

IT 406162-47-8P 406162-54-7P 406162-63-8P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation and structure-activity relationship of quinolinone derivs. as ***farnesyltransferase*** inhibitors)

IT 406162-85-4P 406162-87-6P 654074-98-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and structure-activity relationship of quinolinone derivs. as ***farnesyltransferase*** inhibitors)

IT 192185-51-6 192185-54-9 192185-64-1 192185-72-1, Zarnestra 192185-89-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation and structure-activity relationship of quinolinone derivs. as ***farnesyltransferase*** inhibitors)

IT 74-88-4, reactions 6610-29-3 24854-43-1 26628-22-8, Sodium azide 36635-61-7 192187-33-0 280144-85-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation and structure-activity relationship of quinolinone derivs. as ***farnesyltransferase*** inhibitors)

IT 406161-89-5P 406161-90-8P 406161-91-9P 406161-92-0P 406162-21-8P 406162-22-9P 406162-23-0P 654074-93-8P 654074-95-0P 654074-96-1P 654074-97-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and structure-activity relationship of quinolinone derivs. as ***farnesyltransferase*** inhibitors)

REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:837087 CAPLUS Full-text

DOCUMENT NUMBER: 139:337983
TITLE: Preparation of ***farnesyl*** transferase inhibiting ***tetrazoloquinazolines*** substituted with carbon-linked imidazoles or ***triazoles***
INVENTOR(S): ***Angibaud, Patrick Rene***; Venet, Marc Gaston; Argoullon, Jean Michel Jacques Raymond
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2003087101 | A1 | 20031023 | WO 2003-EP3986 | 20030414 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2481480 | A1 | 20031023 | CA 2003-2481480 | 20030414 |
| AU 2003229688 | A1 | 20031027 | AU 2003-229688 | 20030414 |
| EP 1497295 | A1 | 20050119 | EP 2003-722496 | 20030414 |
| EP 1497295 | B1 | 20060816 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| US 2005148609 | A1 | 20050707 | US 2003-509365 | 20030414 |
| JP 2005526109 | T | 20050902 | JP 2003-584057 | 20030414 |
| AT 336496 | T | 20060915 | AT 2003-722496 | 20030414 |
| PRIORITY APPLN. INFO.: | | | EP 2002-76448 A | 20020415 |
| | | | WO 2003-EP3986 W | 20030414 |

OTHER SOURCE(S): MARPAT 139:337983
GI



I



II

AB Title compds. I [R1, R2 = (un)substituted Ph; R3 = H, halogen, CN, (un)substituted alkyl, alkenyl, alkynyl, CO2H, aryl, heterocyclic, OH, SH, NH2, N:CH2; R4 = (un)substituted imidazol-5-yl, 4H-1,2,4-***triazol*** -3-yl; R5 = CN, OH, halogen, (un)substituted alkyl, alkenyl, alkynyl, alkoxy, CO2H, NH2, CONH2; R6 = H, (un)substituted alkyl; n = 0-2] were prepared for use as ***farnesyl*** transferase inhibitors in the treatment of proliferative diseases. Thus, the title compound I was prepared by rearrangement of 5-(3-chlorophenyl)-α-(4-chlorophenyl)-4,5- dihydro-α-(1-methyl-1H-imidazol-5-yl)tetrazolo[1,5-a] ***quinazolinemethanol*** and gave 81% inhibition of ***farnesyl*** transferase at 1X10-7 M.

IC ICM C07D487-04
ICS A61K031-519; A61P035-00; C07D257-00

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))

ST ***tetrazoloquinazoline*** prepn ***farnesyl*** transferase inhibitor

IT Antitumor agents
Human
Neoplasm
(preparation of ***farnesyl*** transferase inhibiting ***tetrazoloquinazolines*** substituted with carbon-linked imidazoles or ***triazoles***)

IT Disease, animal
(proliferative; preparation of ***farnesyl*** transferase inhibiting ***tetrazoloquinazolines*** substituted with carbon-linked imidazoles or ***triazoles***)

IT 131384-38-8, ***Farnesyl*** protein transferase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of ***farnesyl*** transferase inhibiting ***tetrazoloquinazolines*** substituted with carbon-linked imidazoles or ***triazoles***)

IT 615277-93-5P 615277-99-1P 615278-09-6P 615278-34-7P 615278-39-2P 615278-42-7P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of ***farnesyl*** transferase inhibiting ***tetrazoloquinazolines*** substituted with carbon-linked imidazoles or ***triazoles***)

IT 615277-96-8P 615278-01-8P 615278-03-0P 615278-06-3P 615278-12-1P 615278-15-4P 615278-18-7P 615278-21-2P 615278-24-5P 615278-27-8P 615278-30-3P 615278-36-9P 615278-40-5P 615278-41-6P 615278-43-8P 615278-44-9P 615278-45-0P 615278-47-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of ***farnesyl*** transferase inhibiting ***tetrazoloquinazolines*** substituted with carbon-linked imidazoles or ***triazoles***)

IT 76-02-8, Trichloroacetyl chloride 104-87-0, 4-Methylbenzaldehyde 459-57-4, 4-Fluorobenzaldehyde 616-47-7, 1-Methyl-1H-imidazole 52898-49-4, N,4-Dimethoxy-N-methylbenzamide 215034-81-4 280143-55-7 288391-73-1 382146-82-9 382146-83-0 406162-04-7 406163-06-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of ***farnesyl*** transferase inhibiting ***tetrazoloquinazolines*** substituted with carbon-linked imidazoles or ***triazoles***)

IT 615277-06-0P 615277-08-2P 615277-10-6P 615277-12-8P 615277-14-0P

615277-16-2P 615277-18-4P 615277-20-8P 615277-22-0P 615277-24-2P
615277-26-4P 615277-28-6P 615277-30-0P 615277-32-2P 615277-34-4P
615277-36-6P 615277-38-8P 615277-40-2P 615277-42-4P 615277-44-6P
615277-46-8P 615277-48-0P 615277-50-4P 615277-52-6P 615277-54-8P
615277-55-9P 615277-57-1P 615277-59-3P 615277-62-8P 615277-63-9P
615277-65-1P 615277-68-4P 615277-74-2P 615277-77-5P 615277-78-6P
615277-80-0P 615277-82-2P 615277-84-4P 615277-88-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of ***farnesyl*** transferase inhibiting ***tetrazoloquinazolines*** substituted with carbon-linked imidazoles or ***triazoles***)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:777590 CAPLUS Full-text

DOCUMENT NUMBER: 139:292244

TITLE: Benzylimidazolyl substituted 2-quinoline and ***quinazoline*** derivatives for use as ***farnesyl*** transferase inhibitors

INVENTOR(S): ***Angibaud, Patrick Rene***; Venet, Marc Gaston; Meyer, Christophe; Breslin, Henry Joseph

PATENT ASSIGNEE(S): Janssen Pharmaceutica NV, Belg.

SOURCE: PCT Int. Appl., 46 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2003080058 | A1 | 20031002 | WO 2003-EP2874 | 20030318 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2478813 | A1 | 20031002 | CA 2003-2478813 | 20030318 |
| AU 2003223970 | A1 | 20031008 | AU 2003-223970 | 20030318 |
| EP 1490065 | A1 | 20041229 | EP 2003-720339 | 20030318 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| US 2005171111 | A1 | 20050804 | US 2003-508185 | 20030318 |
| JP 2005523909 | T | 20050811 | JP 2003-577885 | 20030318 |
| PRIORITY APPLN. INFO.: | | | EP 2002-76157 A | 20020322 |
| | | | WO 2003-EP2874 W | 20030318 |

OTHER SOURCE(S): MARPAT 139:292244

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB This invention comprises the novel compds. I (wherein m = 0-3; n = 0-2; Y1-Y2 = C:N, C:CR8, CHNR8, CHCHR8 (R8 = H, halo, CN, C1-6alkyl, HO, CO); R1 = H, OH, halo, CN, NO2, C1-6alkyl, substituted C3-10cycloalkyl, cyanoC1-6alkyl, hydroxyC1-6alkyl, C1-6alkoxyC1-6alkyl, C1-6alkylamino, trihalomethyl, C2-6alkenyl, C2-6alkynyl, CHO, HO2C, C1-6alkoxycarbonyl, substituted CH:NOH or 2 adjacent R1 substituents = OCH2O, OCH2CH2O, OCH:CH, OCH2CH2; R2 = H, halo, CN, NO2, C1-6alkyl, hydroxyC1-6alkyl, C1-6alkoxyC1-6alkyl, CF3, HO2C, C1-6alkoxycarbonyl, NO2, cyanoC1-6alkyl, C2-6alkenyl, C2-6alkynyl, CHO, substituted CH:NOH or 2 adjacent R2 substituents = OCH2O, OCH2CH2O; R3 = H, OH, halo, C1-6alkyl, haloC1-6alkyl, cyanoC1-6alkyl, aminoC1-6alkyl, substituted C1-6alkylCONH2, mono(di)(C1-6alkylamino)C1-6alkyl, hydroxyC1-6alkyl, C1-6alkoxyC1-6alkyl, carbonylC1-6alkyl, hydroxycarbonylC1-6alkyl, C1-6alkoxycarbonylC1-6alkyl, HO2C, C1-6alkoxycarbonyl etc.; R4 = H, OH, halo, CN. C1-6alkyl, C1-6alkoxy; R5 = H, C1-12alkyl, substituted C3-10cycloalkyl, cyanoC1-6alkyl, substituted C1-6alkylCO2H, aminocarbonylC1-6alkyl, substituted C1-6alkylOH, substituted C1-6alkylSH, CF3, arylC1-6alkyl, heterocycloC1-6alkyl, hydroxyC1-6alkyl, C1-6alkoxyC1-6alkyl, substituted C1-6alkylamine; R6 = O, or R5 + R6 = CH:CHN=, CH:NN=, N:NN=; R7 = H, C1-6alkyl or R3 + R7 = O) having ***farnesyl*** transferase inhibiting activity. Also claimed are their preparation, compns. containing them and their use as a medicine to treat e.g. cancer. For example, II (R8 = Me) was prepared in 27 % yield by methylation of II (R8 = H), which was prepared in a multistep process starting form 1-bromo-4-nitrobenzene and 3-chlorobenzeneacetonitrile in MeOH containing NaOH to give 5-bromo-3-(3-chlorophenyl)-2,1-benzisoxazole which was converted to (2-amino-5-bromophenyl)(3-chlorophenyl)methanone which was converted to 6-bromo-4-(3-chlorophenyl)-2-methoxyquinoline in a 4 step process and then reacted with 4-[(5-formyl-1H-imidazol-2-yl)methyl]benzonitrile. The product of this latter reaction, 3-(3-chlorophenyl)-N-[4-[[(4- cyanophenyl)methyl-1H-imidazol-5-yl]hydroxymethyl]phenyl]-2-propenimidic acid (1E,2E)-Me ester was refluxed in HCl to give II (R8 = H). Film-coated tablets containing I were made.

IC ICM A61K031-4704
ICS A61K031-4709; A61K031-4745; A61P035-00; C07D401-06; C07D487-04

CC 28-7 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63

ST benzylimidazolyl substituted quinoline ***quinazoline*** prepn antitumor agent

IT Antitumor agents
Human
Neoplasm
(preparation of benzylimidazolyl substituted 2-quinoline and ***quinazoline*** derivs. as antitumor agents)

IT Drug delivery systems
(tablets, coated; preparation of benzylimidazolyl substituted 2-quinoline and ***quinazoline*** derivs. as antitumor agents)

IT 607715-98-0P 607715-99-1P 607716-00-7P 607716-01-8P 607716-05-2P
607716-06-3P 607716-07-4P 607716-08-5P 607716-09-6P 607716-10-9P
607716-11-0P 607716-12-1P 607716-13-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzylimidazolyl substituted 2-quinoline and ***quinazoline*** derivs. as antitumor agents)

IT 75-05-8, Acetonitrile, reactions 108-24-7, Acetic acid anhydride
530-62-1, 1,1'-Carbonyldiimidazole 586-78-7, 1-Bromo-4-nitrobenzene
765-30-0, Cyclopropanamine 1529-41-5, 3-Chlorobenzeneacetonitrile
26628-22-8, Sodium azide 183500-37-0 189353-88-6 607716-20-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of benzylimidazolyl substituted 2-quinoline and

***quinazoline*** derivs. as antitumor agents)

IT 190898-86-3P 280143-23-9P 288391-73-1P 288391-74-2P 406161-72-6P
607715-97-9P 607716-02-9P 607716-03-0P 607716-04-1P 607716-14-3P
607716-15-4P 607716-16-5P 607716-17-6P 607716-19-8P 607717-51-1P
607717-51-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzylimidazolyl substituted 2-quinoline and ***quinazoline*** derivs. as antitumor agents)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:737586 CAPLUS Full-text
DOCUMENT NUMBER: 139:261308
TITLE: Preparation of aryl and heteroaryl hydroxamic acids as inhibitors of histone deacetylase for treating proliferative diseases
INVENTOR(S): Van Emelen, Kristof; Verdonck, Marc Gustaaf Celine; Van Brandt, Sven Franciscus Anna; ***Angibaud, Patrick Rene***; Meerpoel, Lieven; Dyatkin, Alexey Borisovich
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2003075929 | A1 | 20030918 | WO 2003-EP2515 | 20030311 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2476065 | A1 | 20030918 | CA 2003-2476065 | 20030311 |
| AU 2003218737 | A1 | 20030922 | AU 2003-218737 | 20030311 |
| EP 1485099 | A1 | 20041215 | EP 2003-711981 | 20030311 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| BR 2003007624 | A | 20050111 | BR 2003-7624 | 20030311 |
| US 2005096468 | A1 | 20050505 | US 2003-507785 | 20030311 |
| CN 1639125 | A | 20050713 | CN 2003-805675 | 20030311 |
| CN 1642551 | A | 20050720 | CN 2003-805833 | 20030311 |
| JP 2005525379 | T | 20050825 | JP 2003-574203 | 20030311 |
| NZ 534832 | A | 20050930 | NZ 2003-534832 | 20030311 |
| ZA 2004007237 | A | 20050928 | ZA 2004-7237 | 20040909 |
| ZA 2004007235 | A | 20051004 | ZA 2004-7235 | 20040909 |
| ZA 2004007232 | A | 20051006 | ZA 2004-7232 | 20040909 |
| ZA 2004007233 | A | 20051006 | ZA 2004-7233 | 20040909 |
| ZA 2004007234 | A | 20051006 | ZA 2004-7234 | 20040909 |
| ZA 2004007236 | A | 20051006 | ZA 2004-7236 | 20040909 |

NO 2004004113 A 20040928 NO 2004-4113 20040928
PRIORITY APPLN. INFO.: US 2002-363799P P 20020313
WO 2003-EP2515 W 20030311

OTHER SOURCE(S): MARPAT 139:261308
GI


I


II

AB This invention comprises aryl and heteroaryl hydroxamic acids (shown as I; variables defined below; e.g. II) having histone deacetylase inhibiting enzymic activity; their preparation, compns. containing them and their use as a medicine. Compds. I show excellent in-vitro histone deacetylase inhibiting enzymic activity, have advantageous properties with regard to cellular activity and specific properties with regard to inhibition of cell cycle progression at both G1 and G2 checkpoints (p21 induction capacity), and show good metabolic stability and high bioavailability and more particular show oral bioavailability. They can also be used for detection and identification of histone deacetylase. General synthetic procedures and characterization data for twenty-seven I are included; also, prepns. of 12 intermediates are included. For example, a 59 % yield of 2-[4-(dimethylaminosulfonyl)piperazin-1-yl]pyrimidine-5-carbohydroxamic acid was obtained by removing the O-tetrahydropyranyl group of its ester using trifluoroacetic acid; the ester was prepared in 61 % yield from N'-(ethylcarbonimidoyl)-N,N-dimethyl-1,3-propanediamine monohydrochloride, sodium 2-[4-(dimethylaminosulfonyl)piperazin-1-yl]pyrimidine-5- carboxylate, O-(tetrahydro-2H-pyran-2-yl)hydroxylamine, and 1-hydroxy-1H- ***benzotriazole*** in CH2Cl2/THF. The sodium salt was obtained by base hydrolysis of the Et ester; the ester was prepared in 73 % yield from Et 2-(piperazin-1-yl)pyrimidine-5-carboxylate and dimethylsulfamoyl chloride; Et 2-(piperazin-1-yl)pyrimidine-5-carboxylate was obtained in <96 % yield from Et 2-(4-benzylpiperazin-1-yl)pyrimidine-5-carboxylate by hydrogenation using Pd/C; the benzyl derivative was obtained from 1-(phenylmethyl)piperazine, (135 mL) was added gradually to a solution of potassium carbonate (0.18 mol) and 2-(methylsulfonyl)-5-pyrimidinecarboxylic acid Et ester, K2CO3 in MeCN. For I: n is 0-3; Q, X and Y are N or C; Z is N or CH; R1 is -C(O)NR5R6, -N(H)C(O)R7, -C(O)-C1-6alkanediylSR7, -NR8C(O)N(OH)R7, -NR8C(O)C1-6alkanediylSR7, -NR8C(O)C:N(OH)R7 or another Zn-chelating-group; R2 is H, halo, hydroxy, amino, nitro, C1-6alkyl, C1-6alkyloxy, trifluoromethyl, di(C1-6-alkyl)amino, hydroxyamino or naphthalenylsulfonylpyrazinyl. R3 is H, C1-6-alkyl, arylC2-6alkenediyl, furanylcarbonyl, naphthalenylcarbonyl, -C(O)phenylR9, C1-6alkylaminocarbonyl, aminosulfonyl, arylaminosulfonyl, aminosulfonylamino, di(C1-6-alkyl)aminosulfonylamino, arylaminosulfonylamino, aminosulfonylaminoC1-6-alkyl, di(C1-6- alkyl)aminosulfonylaminoC1-6-alkyl, arylaminosulfonylaminoC1-6alkyl, di(C1-6-alkyl)aminoC1-6alkyl, C11-12-alkylsulfonyl, di(C1-6-alkyl)aminosulfonyl, trihaloC1-6-alkylsulfonyl, di(aryl)C1-6alkylcarbonyl, thiophenylC1-6alkylcarbonyl, pyridinylcarbonyl or arylC1-6alkylcarbonyl. R4 is H, hydroxy, amino, hydroxyC1-6alkyl, C1-6alkyl, C1-6alkyloxy, arylC1-6alkyl, aminocarbonyl, hydroxycarbonyl, aminoC1-6-alkyl, aminocarbonylC1-6-alkyl,

hydroxycarbonylC1-6-alkyl, hydroxyaminocarbonyl, C1-6-alkyloxycarbonyl, C1-6-alkylaminoC1-6-alkyl or di(C1-6-alkyl)aminoC1- 6-alkyl; when R3 and R4 are present on the same C atom, R3 and R4 together may form -C(O)-NH-CH2-NR10- wherein R10 is H or aryl; when R3 and R4 are present on adjacent C atoms, R3 and R4 together may form :CH-CH:CH-CH: ; addnl. details are given in the claims.

IC ICM A61K031-505
ICS A61P035-00; C07D471-10; C07D239-42; C07D401-04; C07D295-14; C07D307-68; C07D217-02; C07D207-09; C07D401-12; C12Q001-34

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:491226 CAPLUS Full-text
DOCUMENT NUMBER: 139:69163
TITLE: 1,8-Annelated quinoline derivatives substituted with carbon-linked ***triazoles*** as ***farnesyl*** transferase inhibitors
INVENTOR(S): ***Angibaud, Patrick Rene***; Venet, Marc Gaston
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2003051880 | A1 | 20030626 | WO 2002-EP14089 | 20021211 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2469275 | A1 | 20030626 | CA 2002-2469275 | 20021211 |
| AU 2002358677 | A1 | 20030630 | AU 2002-358677 | 20021211 |
| EP 1458720 | A1 | 20040922 | EP 2002-792974 | 20021211 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK | | | | |
| JP 2005511790 | T | 20050428 | JP 2003-552764 | 20021211 |
| US 2005176702 | A1 | 20050811 | US 2003-498535 | 20021211 |
| PRIORITY APPLN. INFO.: | | | EP 2001-204989 A | 20011219 |
| | | | WO 2002-EP14089 W | 20021211 |

OTHER SOURCE(S): MARPAT 139:69163
GI




I




II

AB Title compds. I (wherein m, n = 1, 2, or 3; A = CH:CH, CH2CH2, CH2CH2CH2, CH2O, CH2CH2O, optionally substituted with alkyl groups; X = O or S; Y1-Y2 = C:CR5 or CHCHR5; R5 = H, halo, alkyl; R1 = H, OH, halo, CN, NO2, alkenyl, alkynyl, CHO, CO2H, alkoxycarbonyl, CONR14R15, CONR14O-alkyl, CONR14-alkenyl, OCOR16, CR16:NR17, CR16:NOR17, or (un)substituted alkyl, alkoxy, or alkylenylcycloalkyl; R2 = H, OH, halo, CN, NO2, alkyl, alkoxy, trihalomethyl, alkylthio, dialkylamino, alkenyl, CO2H, alkoxycarbonyl, CONR14R15, etc.; or R1R2 = OCH2O, OCH2CH2O, OCH:CH, or OCH2CH2; R3 = H, halo, (un)substituted alkyl, alkylenylcycloalkyl, heterocyclyl, etc.; R4 = H or alkyl; R14, R15 , R16, and R17 = independently H, alkyl, or (un)substituted alkylenylcycloalkyl) were prepared as ***farnesyl*** transferase inhibitors. For example, the 4H-pyrrolo[3,2,1-ij]quinolin-4- one II was prepared by removal of a mercapto group from an intermediate prepared in 6 steps using (±)-6-(3-chlorophenyl)-1,2,5,6-tetrahydro-4H- pyrrolo[3,2,1-ij]quinolin-4-one and 4-iodobenzoic acid as starting materials. The latter inhibited ***farnesyl*** protein transferase with a pIC50 value of 7.669. Thus, compns. containing I are useful for the treatment of proliferative disorders, such as cancer (no data).

IC ICM C07D471-06
ICS C07D498-06; A61K031-47; A61P035-00

CC 27-17 (Heterocyclic Compounds (One Hetero Atom))

ST annelated quinoline deriv prepn ***farnesyl*** transferase inhibitor antitumor agent

IT Antitumor agents
Cytotoxic agents
Neoplasm
(preparation of ***triazolyl***-substituted 1,8-annelated quinolines as ***farnesyl*** transferase inhibitors for treatment of cancer)

IT 550357-45-4P, 6-(3-Chlorophenyl)-1,2,5,6-tetrahydro-8-(4-iodobenzoyl)-4H-pyrrolo[3,2,1-ij]quinolin-4-one 550357-46-5P, 6-(3-Chlorophenyl)-1,2-dihydro-8-(4-iodobenzoyl)-4H-pyrrolo[3,2,1-ij]quinolin-4-one 550357-47-6P 550357-48-7P 550357-51-2P 550357-52-3P, 5-Bromo-1-[(2E)-3-(3-chlorophenyl)-1-oxo-2-propenyl]-2,3-dihydro-1H-indole 550357-53-4P, 8-Bromo-6-(3-chlorophenyl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one 550357-54-5P, 8-Bromo-6-(3-chlorophenyl)-1,2-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one 550357-55-6P, 6-(3-Chlorophenyl)-1,2-dihydro-N-methoxy-N-methyl-4-oxo-4H-pyrrolo[3,2,1-ij]quinoline-8-carboxamide 550357-56-7P, 8-Benzoyl-6-(3-chlorophenyl)-1,2-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one 550357-59-0P 550357-60-3P 550357-61-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of ***triazolyl***-substituted 1,8-annelated quinolines as ***farnesyl*** transferase inhibitors for treatment of cancer)

IT 131384-38-8, ***Farnesyltransferase***

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of ***triazolyl***-substituted 1,8-annelated quinolines as ***farnesyl*** transferase inhibitors for treatment of cancer)

IT 550357-34-1P, 6-(3-Chlorophenyl)-1,2-dihydro-8-[(4-iodophenyl)(4-methyl-4H-1,2,4-***triazol***-3-yl)methyl]-4H-pyrrolo[3,2,1-ij]quinolin-4-one 550357-35-2P, 4-[[6-(3-Chlorophenyl)-1,2-dihydro-4-oxo-4H-pyrrolo[3,2,1-ij]quinolin-8-yl](4-methyl-4H-1,2,4-***triazol***-3-yl)methyl]-benzonitrile 550357-36-3P 550357-37-4P 550357-38-5P 550357-39-6P 550357-40-9P, N-[[6-(3-Chlorophenyl)-1,2-dihydro-4-oxo-4H-pyrrolo[3,2,1-ij]quinolin-8-yl](4-fluorophenyl)(4-methyl-4H-1,2,4-***triazol***-3-yl)methyl]-acetamide 550357-41-0P 550357-42-1P, 6-(3-Chlorophenyl)-8-[(4-fluorophenyl)(2-hydroxyethoxy)(4-methyl-4H-1,2,4-***triazol***-3-yl)methyl]-1,2-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one 550357-43-2P 550357-44-3P, 8-[Amino(4-fluorophenyl)(4-methyl-4H-1,2,4-***triazol***-3-yl)methyl]-6-(3-chlorophenyl)-1,2-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one 550357-58-9P 550357-62-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of ***triazolyl***-substituted 1,8-annelated quinolines as ***farnesyl*** transferase inhibitors for treatment of cancer)

IT 619-58-9, 4-Iodo-benzoic acid 6638-79-5, N-Methoxy-methanamine,hydrochloride 22190-33-6, 5-Bromo-2,3-dihydro-1H-indole 24854-43-1, 2,4-Dihydro-4-methyl-3H-1,2,4-***triazole***-3-thione 39096-24-7, 3-(3-Chlorophenyl)-2-propenoyl chloride 213389-68-5, 6-(3-Chlorophenyl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one 213389-74-3 213389-78-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of ***triazolyl***-substituted 1,8-annelated quinolines as ***farnesyl*** transferase inhibitors for treatment of cancer)

IT 550357-49-8P 550357-50-1P, 6-(3-Chlorophenyl)-1,2-dihydro-8-[(4-iodophenyl)(5-mercapto-4-methyl-4H-1,2,4-***triazol***-3-yl)methyl]-4H-pyrrolo[3,2,1-ij]quinolin-4-one 550357-57-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of ***triazolyl***-substituted 1,8-annelated quinolines as ***farnesyl*** transferase inhibitors for treatment of cancer)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:293606 CAPLUS Full-text
DOCUMENT NUMBER: 139:197461
TITLE: 5-Imidazolylquinolinones, -***quinazolinones***, and -benzoazepinones as ***farnesyltransferase*** inhibitors
AUTHOR(S): ***Angibaud, Patrick***; Bourdrez, Xavier; Devine, Ann; End, David W.; Freyne, Eddy; Ligny, Yannick; Muller, Philippe; Mannens, Geert; Pilatte, Isabelle; Poncelet, Virginie; Skrzat, Stacy; Smets, Gerda; Van Dun, Jacky; Van Remoortere, Pieter; Venet, Marc; Wouters, Walter
CORPORATE SOURCE: Medicinal Chemistry Department, Johnson & Johnson Pharmaceutical Research & Development, Val de Reuil, 27106, Fr.
SOURCE: Bioorganic & Medicinal Chemistry Letters (2003), 13(9), 1543-1547
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal

LANGUAGE: English
OTHER SOURCE(S): CASREACT 139:197461
GI




I

AB The evaluation of structure-activity relationships associated with the modification of the R115777 quinolinone ring moiety displaying potent in vitro inhibiting activity is described. E.g., pyrrol[3,2,1-ij]quinolin-4- one I, an analog of R115777, was prepared from 2,3-dihydroindole and its ***farnesyltransferase***-inhibiting activity was determined

CC 28-22 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1

ST imidazolyl quinolinone ***quinazolinone*** benzoazepinone prepn ***farnesyltransferase*** inhibitor

IT Structure-activity relationship
(***farnesyltransferase***-inhibiting; preparation of imidazolylquinolinones, -***quinazolinones***, and -benzoazepinones as ***farnesyltransferase*** inhibitors)

IT Antitumor agents
Neoplasm
(preparation of imidazolylquinolinones, -***quinazolinones***, and -benzoazepinones as ***farnesyltransferase*** inhibitors)

IT 192185-68-5, R115777
RL: PAC (Pharmacological activity); BIOL (Biological study)
(preparation of R115777 analogs as ***farnesyltransferase*** inhibitors)

IT 131384-38-8, ***Farnesyltransferase***
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of imidazolylquinolinones, -***quinazolinones***, and -benzoazepinones as ***farnesyltransferase*** inhibitors)

IT 213388-97-7P 213388-98-8P
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of imidazolylquinolinones, -***quinazolinones***, and -benzoazepinones as ***farnesyltransferase*** inhibitors)

IT 213388-93-3P 213388-99-9P 213389-03-8P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(preparation of imidazolylquinolinones, -***quinazolinones***, and -benzoazepinones as ***farnesyltransferase*** inhibitors)

IT 213388-96-6P 213389-01-6P 213389-02-7P 213389-04-9P 215034-66-5P 432552-86-8P 432552-87-9P 432553-04-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of imidazolylquinolinones, -***quinazolinones***, and -benzoazepinones as ***farnesyltransferase*** inhibitors)

IT 74-11-3, 4-Chlorobenzoic acid 91-23-6 122-01-0 496-15-1 616-47-7,

1-Methylimidazole 635-46-1 1529-41-5, 3-Chlorobenzyl cyanide
7497-60-1 39096-24-7 190898-77-2 190898-78-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of imidazolylquinolinones, -***quinazolinones***, and -benzoazepinones as ***farnesyltransferase*** inhibitors)

IT 192187-40-9P 213389-43-6P 213389-44-7P 213389-45-8P 213389-46-9P
213389-48-1P 213389-54-9P 213389-55-0P 213389-70-9P 213389-71-0P
213389-74-3P 213389-75-4P 215034-62-1P 215034-81-4P 215034-82-5P
215034-86-9P 432552-77-7P 432552-78-8P 432552-79-9P 432552-82-4P
432552-84-6P 432553-05-4P 432553-10-1P 544690-75-7P 586346-38-5P
586346-39-6P 586346-40-9P 586346-41-0P 586346-42-1P 586346-43-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of imidazolylquinolinones, -***quinazolinones***, and -benzoazepinones as ***farnesyltransferase*** inhibitors)

REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:504781 CAPLUS Full-text
DOCUMENT NUMBER: 137:78964
TITLE: Preparation of ***farnesyl*** transferase inhibiting 4-substituted quinolines and ***quinazolines***
INVENTOR(S): ***Angibaud, Patrick Rene***; Venet, Marc Gaston
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 67 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2002051835 | A1 | 20020704 | WO 2001-EP15234 | 20011221 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| EP 1347966 | A1 | 20031001 | EP 2001-988065 | 20011221 |
| EP 1347966 | B1 | 20060308 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| JP 2004516323 | T | 20040603 | JP 2002-552930 | 20011221 |
| AT 319704 | T | 20060315 | AT 2001-988065 | 20011221 |
| ES 2260316 | T3 | 20061101 | ES 2001-1988065 | 20011221 |
| US 2004063944 | A1 | 20040401 | US 2003-451902 | 20030626 |
| US 7129356 | B2 | 20061031 | | |

PRIORITY APPLN. INFO.: EP 2000-204715 A 20001227
WO 2001-EP15234 W 20011221

OTHER SOURCE(S): MARPAT 137:78964
GI



I

AB The title compds. [I; r, s = 0-5; t = 0-3; Y1Y2 = C:N, C:CR9, CHNR9, CHCHR9 (wherein R9 = H, halo, CN, etc.); Z = O, S, SO, etc.; R1, R2 = N3, OH, halo, etc.; R3 = H, halo, CN, etc.; R4 = (un)substituted imidazolyl, ***triazolyl***, pyridyl; R5 = CN, OH, halo, etc.; R6 = H, alkyl, cyanoalkyl, etc.; R7 = O, S; or R6 and R7 together form CONHN, N:NN, etc.] having ***farnesyl*** transferase inhibiting activity (no biol. data), were prepared and formulated. E.g., a multi-step synthesis of I [r = 0; s = 1; t = 0; Y1Y2 = C:CH; Z = O; R2 = 4-Cl; R3 = H; R4 = 1-imidazolyl; R6 = H; R7 = O] was given.

IC ICM C07D401-06
ICS A61K031-47; A61P035-00; C07D403-06

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63

ST quinoline ***quinazoline*** prepn formulation ***farnesyl*** transferase inhibitor antitumor

IT Antitumor agents
Human
Neoplasm
(preparation of ***farnesyl*** transferase inhibiting 4-substituted quinolines and ***quinazolines***)

IT 131384-38-8, ***Farnesyl*** transferase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of ***farnesyl*** transferase inhibiting 4-substituted quinolines and ***quinazolines***)

IT 439906-16-8P 439906-17-9P 439906-18-0P 439906-21-5P 439906-23-7P
439906-29-3P 439906-35-1P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of ***farnesyl*** transferase inhibiting 4-substituted quinolines and ***quinazolines***)

IT 439906-15-7P 439906-19-1P 439906-20-4P 439906-22-6P 439906-24-8P
439906-25-9P 439906-26-0P 439906-27-1P 439906-28-2P 439906-30-6P
439906-31-7P 439906-32-8P 439906-33-9P 439906-34-0P 439906-36-2P
439906-37-3P 439906-38-4P 439906-39-5P 439906-40-8P 439906-42-0P
439906-44-2P 439906-46-4P 439906-48-6P 439906-50-0P 439906-52-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of ***farnesyl*** transferase inhibiting 4-substituted quinolines and ***quinazolines***)

IT 78-94-4, 3-Buten-2-one, reactions 87-13-8, (Ethoxymethylene)propanedioic acid diethyl ester 87-48-9, 5-Bromo-1H-indole-2,3-dione 100-44-7,

(Chloromethyl)benzene, reactions 108-43-0, 3-Chlorophenol 108-44-1, 3-Methylaniline, reactions 109-86-4, 2-Methoxyethanol 530-62-1, 1,1'-Carbonyldiimidazole 616-47-7, 1-Methyl-1H-imidazole 618-48-4, 3-Chlorobenzamide 620-20-2, 1-Chloro-3-(chloromethyl)benzene 626-55-1, 3-Bromopyridine 670-96-2, 2-Phenyl-1H-imidazole 4913-77-3, (4-Aminophenyl)(4-chlorophenyl)methanone 24854-43-1, 2,4-Dihydro-4-methyl-3H-1,2,4-***triazole***-3-thione 122334-37-6, 4-Chloro-N-methoxy-N-methylbenzamide 190898-64-7 439868-77-6 439906-99-7 439907-00-3 439907-01-4 439907-02-5 439907-03-6 439907-04-7 439907-05-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of ***farnesyl*** transferase inhibiting 4-substituted quinolines and ***quinazolines***)

IT 439868-39-0P, Ethyl 6-(4-chlorobenzoyl)-4-hydroxy-3-quinolinecarboxylate 439868-40-3P, 6-(4-Chlorobenzoyl)-4-hydroxy-3-quinolinecarboxylic acid 439868-41-4P, (4-Chlorophenyl)(4-hydroxy-6-quinolinyl)methanone 439868-42-5P, (4-Chlorophenyl)(4-chloro-6-quinolinyl)methanone 439868-56-1P, (4-Chlorophenyl)(4-methyl-6-quinolinyl)methanone 439868-70-9P 439906-54-4P, 6-(4-Chlorobenzoyl)-4-phenoxy-2(1H)-quinolinone 439906-56-6P 439906-58-8P 439906-60-2P 439906-62-4P 439906-64-6P 439906-66-8P 439906-67-9P 439906-69-1P 439906-71-5P 439906-73-7P 439906-74-8P 439906-75-9P 439906-77-1P 439906-79-3P 439906-80-6P 439906-81-7P 439906-82-8P 439906-83-9P 439906-84-0P 439906-85-1P 439906-86-2P 439906-87-3P 439906-88-4P 439906-89-5P 439906-90-8P, 5-Bromo-1,3-dihydro-3,3-dimethoxy-2H-indol-2-one 439906-91-9P, 5-(4-Chlorobenzoyl)-1,3-dihydro-3,3-dimethoxy-2H-indol-2-one 439906-92-0P, 5-(4-Chlorobenzoyl)-1H-indole-2,3-dione 439906-93-1P, 1-Acetyl-5-(4-chlorobenzoyl)-1H-indole-2,3-dione 439906-94-2P, 6-(4-Chlorobenzoyl)-1,2-dihydro-2-oxo-4-quinolinecarboxylic acid 439906-95-3P 439906-96-4P 439906-97-5P 439906-98-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of ***farnesyl*** transferase inhibiting 4-substituted quinolines and ***quinazolines***)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:504780 CAPLUS Full-text
DOCUMENT NUMBER: 137:63253
TITLE: Preparation of ***farnesyl*** transferase inhibiting 4-heterocyclylquinolines and 4-***heterocyclylquinazolines***
INVENTOR(S): ***Angibaud, Patrick Rene***; Venet, Marc Gaston; Poncelet, Virginie Sophie
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2002051834 | A1 | 20020704 | WO 2001-EP15232 | 20011221 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,

PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

| | | | | |
|---|---|---|---|---|
| EP 1351954 | A1 | 20031015 | EP 2001-995712 | 20011221 |
| EP 1351954 | B1 | 20060503 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| JP 2004516322 | T | 20040603 | JP 2002-552929 | 20011221 |
| AT 325116 | T | 20060615 | AT 2001-995712 | 20011221 |
| PT 1351954 | T | 20060929 | PT 2001-995712 | 20011221 |
| US 2004067968 | A1 | 20040408 | US 2003-250381 | 20030626 |
| US 2006135769 | A1 | 20060622 | US 2006-348593 | 20060207 |
| PRIORITY APPLN. INFO.: | | | EP 2000-204716 A | 20001227 |
| | | | WO 2001-EP15232 W | 20011221 |
| | | | US 2003-250381 A1 | 20030626 |

OTHER SOURCE(S): MARPAT 137:63253

GI



I


AB The title compds. [I; s = 0-5; t = 0-3; Y1Y2 = C:N, C:CR9, CHNR9,CHCHR9 (wherein R9 = H, halo, CN, etc,); R1 = ZHet (Z = a bond, O, S, etc.; Het = (un)substituted monocyclic or bicyclic heterocyclic ring containing one or more heteroatoms selected from O, S and N); R2 = N3, OH, halo, etc.; R3 = H, halo, CN, etc.; R4 = (un)substituted imidazolyl, ***triazolyl***, pyridyl; R5 = CN, OH, halo, etc.; R6 = H, alkyl, cyanoalkyl, etc.; R7 = O, S; or R6 and R7 together from N:NN, CONHN, etc.] having ***farnesyl*** transferase inhibiting activity and useful in inhibiting tumor growth (no biol. data), were prepared and formulated. E.g., a multi-step synthesis of quinolinone I [s = 1; t = 0; Y1Y2 = C:CH; R1 = 1H-imidazol-1-yl; R2 = 4-Cl; R3 = H; R4 = 1H-imidazol-1-yl; R6 = H; R7 = O] was given.


IC ICM C07D401-06
ICS C07D409-06; C07D417-06; C07D413-06; A61K031-47; A61P035-00

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63

ST ***farnesyl*** protein transferase inhibitor heterocyclyl quinoline ***quinazoline*** prepn antitumor

IT Antitumor agents
Human
(preparation of ***farnesyl*** transferase inhibiting 4-heterocyclylquinolines and 4-***heterocyclylquinazolines***)

IT Neoplasm
(treatment of; preparation of ***farnesyl*** transferase inhibiting 4-heterocyclylquinolines and 4-***heterocyclylquinazolines***)

IT 131384-38-8, ***Farnesyl*** protein transferase

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of ***farnesyl*** transferase inhibiting
4-heterocyclylquinolines and 4-***heterocyclylquinazolines***)

IT 439868-20-9P 439868-29-8P 439868-30-1P 439868-32-3P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of ***farnesyl*** transferase inhibiting
4-heterocyclylquinolines and 4-***heterocyclylquinazolines***)

IT 439868-17-4P 439868-18-5P 439868-19-6P 439868-21-0P 439868-22-1P
439868-23-2P 439868-24-3P 439868-25-4P 439868-26-5P 439868-27-6P
439868-28-7P 439868-31-2P 439868-33-4P 439868-34-5P 439868-35-6P
439868-36-7P 439868-37-8P 439868-38-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of ***farnesyl*** transferase inhibiting
4-heterocyclylquinolines and 4-***heterocyclylquinazolines***)

IT 70-11-1, 2-Bromo-1-phenylethanone 78-94-4, 3-Buten-2-one, reactions
78-95-5, 1-Chloro-2-propanone 288-32-4, 1H-Imidazole, reactions
616-47-7, 1-Methyl-1H-imidazole 626-55-1, 3-Bromopyridine 4913-77-3
17341-93-4, 2,2,2-Trichloroethyl chloroformate 19165-25-4 20893-30-5,
2-Thiopheneacetonitrile 23784-96-5, 2-Chloro-5-chloromethylthiophene
190898-64-7 213389-81-2 439868-77-6 439868-78-7 439868-79-8
439868-80-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of ***farnesyl*** transferase inhibiting
4-heterocyclylquinolines and 4-***heterocyclylquinazolines***)

IT 439868-39-0P 439868-40-3P 439868-41-4P 439868-42-5P 439868-43-6P
439868-44-7P 439868-45-8P 439868-46-9P 439868-47-0P 439868-48-1P
439868-49-2P 439868-50-5P 439868-51-6P 439868-52-7P 439868-53-8P
439868-54-9P 439868-55-0P 439868-56-1P 439868-57-2P 439868-58-3P
439868-59-4P 439868-60-7P 439868-61-8P 439868-62-9P 439868-63-0P
439868-64-1P 439868-65-2P 439868-66-3P 439868-67-4P 439868-68-5P
439868-69-6P 439868-70-9P 439868-71-0P 439868-72-1P 439868-73-2P
439868-74-3P 439868-75-4P 439868-76-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of ***farnesyl*** transferase inhibiting
4-heterocyclylquinolines and 4-***heterocyclylquinazolines***)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:408669 CAPLUS Full-text
DOCUMENT NUMBER: 137:6204
TITLE: Preparation of ***farnesyl*** transferase inhibiting benzoheterocyclic derivatives
INVENTOR(S): ***Angibaud, Patrick Rene***; Venet, Marc Gaston; Poncelet, Virginie Sophie
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|

| | | | | | |
|---|---|---|---|---|---|
| WO 2002042296 | A1 | 20020530 | WO 2001-EP13317 | | 20011115 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | | |
| AU 200214056 | A | 20020603 | AU 2002-14056 | | 20011115 |
| EP 1339709 | A1 | 20030903 | EP 2001-982492 | | 20011115 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | | |
| JP 2004514677 | T | 20040520 | JP 2002-544430 | | 20011115 |
| US 2004034218 | A1 | 20040219 | US 2003-432292 | | 20030519 |
| US 7153958 | B2 | 20061226 | | | |
| PRIORITY APPLN. INFO.: | | | EP 2000-204149 | A | 20001121 |
| | | | WO 2001-EP13317 | W | 20011115 |

OTHER SOURCE(S): MARPAT 137:6204


GI



I



II


AB The title compds. [I; r, s = 0-5; t = 0-3; X = NH, O, S, N; Z = (un)substituted alkanediyl; R1, R2 = N3, OH, halo, etc.; or two R1 or R2 adjacent to one another on the Ph ring may form together = OCH2O, OCH2CH2O, OCH:CH, OCH2CH2, O(CH2)3, CH:CHCH:CH; R3 = H, halo, CN, etc.; R4 = (un)substituted imidazolyl, ***triazolyl***, pyridyl, etc.; R5 = CN, OH, halo, etc.; R6 = H, alkyl, CF3, etc.; R7 = O, S; or R6 and R7 together form -N:NN=, -C(O)NHN=, -CR30:CR31N=, etc.; R30, R31 = H, alkyl, CN, etc.] having ***farnesyl*** transferase inhibiting activity, and useful in inhibiting tumor growth, were prepared and formulated. Thus, cyclization of 2-bromo-N-{2-[(3-chlorophenyl)hydroxymethyl]-4-[(4-chlorophenyl)hydroxy(1- methyl-1H-imidazol-5-yl)methyl]phenyl}acetamide (preparation given) in the presence of 2-methyl-2-propanol potassium salt in 2-propanol afforded 11% II.



IC ICM C07D413-06
ICS C07D417-06; C07D403-06; C07D498-04; A61K031-5513; A61K031-553; A61K031-554; A61K031-395; A61P035-00; C07D498-04; C07D267-00; C07D257-00

CC 28-22 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63

ST benzoheterocyclic prepn formulation ***farnesyl*** transferase inhibition antitumor; benzoxazepine prepn formulation ***farnesyl***

transferase inhibition antitumor; benzothiazepine prepn formulation ***farnesyl*** transferase inhibition antitumor; benzodiazepine prepn formulation ***farnesyl*** transferase inhibition antitumor

IT Antitumor agents
(preparation of ***farnesyl*** transferase inhibiting benzoheterocyclic derivs.)

IT 131384-38-8, ***Farnesyltransferase***
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of ***farnesyl*** transferase inhibiting benzoheterocyclic derivs.)

IT 432552-77-7P 432552-78-8P 432552-82-4P 432552-85-7P 432552-87-9P
432552-89-1P 432552-90-4P 432552-91-5P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of ***farnesyl*** transferase inhibiting benzoheterocyclic derivs.)

IT 432552-79-9P 432552-80-2P 432552-81-3P 432552-83-5P 432552-84-6P
432552-86-8P 432552-88-0P 432552-92-6P 432552-93-7P 432552-94-8P
432552-95-9P 432552-96-0P 432552-97-1P 432552-98-2P 432552-99-3P
432553-00-9P 432553-01-0P 432553-02-1P 432553-03-2P 432553-04-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of ***farnesyl*** transferase inhibiting benzoheterocyclic derivs.)

IT 140-29-4, Benzeneacetonitrile 288-32-4, 1H-Imidazole, reactions
616-47-7, 1-Methyl-1H-imidazole 623-33-6, Glycine ethyl ester hydrochloride 626-55-1, 3-Bromopyridine 7051-34-5, (Bromomethyl)cyclopropane 190898-64-7 190898-78-3 192187-40-9
215034-79-0 432553-37-2 432553-38-3 432553-39-4 432553-40-7
432553-41-8 432553-42-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of ***farnesyl*** transferase inhibiting benzoheterocyclic derivs.)

IT 432553-05-4P 432553-06-5P 432553-07-6P 432553-08-7P 432553-09-8P
432553-10-1P 432553-11-2P 432553-12-3P 432553-13-4P 432553-14-5P
432553-15-6P 432553-16-7P 432553-17-8P 432553-18-9P 432553-20-3P
432553-21-4P 432553-22-5P 432553-23-6P 432553-24-7P 432553-25-8P
432553-26-9P 432553-27-0P 432553-28-1P 432553-29-2P 432553-30-5P
432553-31-6P 432553-32-7P 432553-33-8P 432553-34-9P 432553-35-0P
432553-36-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of ***farnesyl*** transferase inhibiting benzoheterocyclic derivs.)

IT 432553-19-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of ***farnesyl*** transferase inhibiting benzoheterocyclic derivs.)

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:240764 CAPLUS Full-text
DOCUMENT NUMBER: 136:279472
TITLE: Preparation of 6-heterocyclylmethyl quinolinone derivatives as ***farnesyl*** transferase inhibitors for treatment of tumors and proliferative diseases

INVENTOR(S): ***Angibaud, Patrick Rene***; Venet, Marc Gaston; Mevellec, Laurence Anne
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2002024687 | A1 | 20020328 | WO 2001-EP10975 | 20010918 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2001093835 | A5 | 20020402 | AU 2001-93835 | 20010918 |
| EP 1322644 | A1 | 20030702 | EP 2001-974284 | 20010918 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| JP 2004521863 | T | 20040722 | JP 2002-529097 | 20010918 |
| US 2003199547 | A1 | 20031023 | US 2003-381362 | 20030324 |
| US 7067531 | B2 | 20060627 | | |

PRIORITY APPLN. INFO.:
EP 2000-203368 A 20000925
EP 2001-202189 A 20010607
WO 2001-EP10975 W 20010918

OTHER SOURCE(S): MARPAT 136:279472
GI



I



II

AB Title compds. I [wherein m = independently 0-5; q = 0-3; Y1Y2 = C:CR9 or CHCHR9; C9 = H, halo, CN, (cyclo)alkyl, hydroxyalkyl, alkoxy(alkyl), aminoalkyl, (amino)alkenyl, (amino)alkynyl, halocarbonyl, hydroxycarbonyl, alkoxycarbonyl, aryl, (un)substituted amino or carbamoyl, etc.; R1 = azido, OH, halo, CN, NO2, trihalomethyl, alkoxy, aryloxy, heterocyclyloxy, alkylthio, or (un)substituted (cyclo)alkyl, alkenyl, alkynyl, carbamoyl, amino, sulfamoyl, etc.; or 2 adjacent R1 = OCH2O, OCH2CH2O, OCH:CH, OCH2CH2, OCH2CH2CH2, CH:CHCH:CH; R2 = (un)substituted mono- or bicyclic heterocyclic ring; R3 = H, halo, CN, alkenyl, alkynyl, hydroxycarbonyl, alkoxycarbonyl, aryl, heterocyclyl, alkoxy, alkylthio, (un)substituted (cyclo)alkyl or amino,

etc.; R4 = (un)substituted imidazolyl, ***triazolyl***, or pyridyl; R5 = CN, OH, halo, alkenyl, alkynyl, hydroxycarbonyl, alkoxycarbonyl, or (un)substituted (cyclo)alkyl, alkoxy, amino, or carbamoyl, etc.; R6 = halo or (un)substituted (cyclo)alkyl, alkenyl, alkynyl, alkylthio, carboxy, carbamoyl, acyl(amino), etc.; R7 = O or S; or R6R7 = (un)substituted CH:CHN:, CH:NN:, CONHN:, N;NN:, N:CHN:, CH:CHCH:, CH:NCH:, CONHCH:, N:NCH:, or CH2(CH2)0-1CH2N: ; or pharmaceutically acceptable salts, N-oxides, or stereochem. isomeric forms thereof] were prepared For example, cyclization of N-[4-bromo-2-(3-chlorobenzoyl)phenyl]acetamide (3-step preparation given) using t-BuOH•K in DME afforded 6-bromo-4-(3-chlorophenyl)-2(1H)-quinoline (80.76%), which was then methoxylated (86%). Addition of bis(1-methyl-1H-imidazol-5- yl)methanone in the presence of BuLi in THF to give the α,α-bis(1-methyl-1H-imidazol-5-yl)-6-quinolinemethanol (5%), followed by reflux in HCl and THF overnight, produced18 II•2HCl (quant.). I have potent ***farnesyl*** transferase inhibitory effect and are useful for inhibiting proliferative diseases and growth of tumors expressing an activated ras oncogene (no data).

IC ICM C07D409-14
ICS A61K031-47; A61P043-00; C07D401-14; C07D521-00; C07D417-14; C07D405-14

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1

ST quinoline prepn ***farnesyl*** transferase inhibitor; antitumor antiproliferative quinoline prepn

IT Antitumor agents
Cytotoxic agents
(preparation of quinoline derivs. as ***farnesyl*** transferase inhibitors for treatment of tumors and proliferative diseases)

IT Ras proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of quinoline derivs. as ***farnesyl*** transferase inhibitors for treatment of tumors and proliferative diseases)

IT 406216-70-4P, 4-(3-Chlorophenyl)-6-[hydroxybis(1-methyl-1H-imidazol-5-yl)methyl]-2(1H)-quinolinone dihydrochloride 406216-80-6P, 4-(3-Chlorophenyl)-6-[3-furanylhydroxy(1-methyl-1H-imidazol-5-yl)methyl]-1-methyl-2(1H)-quinolinone
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(***farnesyl*** transferase inhibitor; preparation of quinolinone derivs. as ***farnesyl*** transferase inhibitors for treatment of tumors and proliferative diseases)

IT 406216-72-6P, 4-(3-Chlorophenyl)-6-[hydroxybis(1-methyl-1H-imidazol-5-yl)methyl]-1-methyl-2(1H)-quinolinone ethanedioate (1:2) 406216-74-8P, 4-(3-Chlorophenyl)-6-[methoxy(1-methyl-1H-imidazol-5-yl)-2-thiazolylmethyl]-1-methyl-2(1H)-quinolinone ethanedioate 406216-75-9P, 4-(3-Chlorophenyl)-6-[hydroxy(1-methyl-1H-imidazol-5-yl)-2-thiazolylmethyl]-1-methyl-2(1H)-quinolinone 406216-78-2P, 4-(3-Chlorophenyl)-3-(hydroxymethyl)-6-[(2-phenyl-1H-imidazol-1-yl)(4-phenyl-2-thiazolyl)methyl]-2(1H)-quinolinone ethanedioate 406216-79-3P, 6-[(1H-Benzimidazol-1-yl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone 406216-81-7P, 4-(3-Chlorophenyl)-6-[hydroxy(1-methyl-1H-imidazol-2-yl)(1-methyl-1H-imidazol-5-yl)methyl]-1-methyl-2(1H)-quinolinone 406216-83-9P, 6-[Amino(3-furanyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone 406216-84-0P, 6-[(1H-1,2,3-***Benzotriazol***-1-yl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone 406216-85-1P, 4-(3-Chlorophenyl)-1-methyl-6-[(1-methyl-1H-imidazol-5-yl)(2-phenyl-1H-imidazol-1-yl)methyl]-2(1H)-quinolinone 406216-86-2P, 4-(3-Chlorophenyl)-6-[(2-ethyl-1H-imidazol-1-yl)(1-methyl-1H-

imidazol-5-yl)methyl]-1-methyl-2(1H)-quinolinone 406216-87-3P, 4-(3-Chlorophenyl)-1-methyl-6-[(1-methyl-1H-imidazol-5-yl)(4-methyl-1H-imidazol-1-yl)methyl]-2(1H)-quinolinone 406216-89-5P 406216-90-8P 406216-91-9P 406216-92-0P 406216-93-1P 406216-94-2P 406216-95-3P 406216-96-4P 406216-97-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(***farnesyl*** transferase inhibitor; preparation of quinolinone derivs. as ***farnesyl*** transferase inhibitors for treatment of tumors and proliferative diseases)

IT 65247-25-8P, (2-Amino-5-bromophenyl)(3-chlorophenyl)methanone 190898-86-3P, 6-Bromo-4-(3-chlorophenyl)-2-methoxyquinoline 280143-23-9P, 6-Bromo-2-chloro-4-(3-chlorophenyl)quinoline 288391-74-2P, 6-Bromo-4-(3-chlorophenyl)-2(1H)-quinolinone 406161-71-5P, 5-Bromo-3-(3-chlorophenyl)-2,1-benzisoxazole 406161-72-6P, N-[4-Bromo-2-(3-chlorobenzoyl)phenyl]acetamide 406216-48-6P, 4-(3-Chlorophenyl)-2-methoxy-α,α-bis(1-methyl-1H-imidazol-5-yl)-6-quinolinemethanol 406216-49-7P, 4-(3-Chlorophenyl)-2-methoxy-α-(1-methyl-1H-imidazol-5-yl)-6-quinolinemethanol 406216-50-0P, [4-(3-Chlorophenyl)-2-methoxy-6-quinolinyl](1-methyl-1H-imidazol-5-yl)methanone 406216-51-1P, 4-(3-Chlorophenyl)-2-methoxy-α-(1-methyl-1H-imidazol-5-yl)-α-(2-thiazolyl)-6-quinolinemethanol 406216-52-2P, 4-(3-Chlorophenyl)-6-[hydroxy(1-methyl-1H-imidazol-5-yl)-2-thiazolylmethyl]-2(1H)-quinolinone 406216-53-3P, 3-(3-Chlorophenyl)-5-(1,3-dioxolan-2-yl)-2,1-benzisoxazole 406216-54-4P, 3-(3-Chlorophenyl)-2,1-benzisoxazole-5-carboxaldehyde 406216-55-5P, 3-(3-Chlorophenyl)-α-(4-phenyl-2-thiazolyl)-2,1-benzisoxazole-5-methanol 406216-56-6P, [3-(3-Chlorophenyl)-2,1-benzisoxazol-5-yl](4-phenyl-2-thiazolyl)methanone 406216-57-7P, [4-Amino-3-(3-chlorobenzoyl)phenyl](4-phenyl-2-thiazolyl)methanone 406216-58-8P, N-[2-(3-Chlorobenzoyl)-4-[(4-phenyl-2-thiazolyl)carbonyl]phenyl]-3-oxo-β-alanine ethyl ester 406216-59-9P, Ethyl 4-(3-chlorophenyl)-1,2-dihydro-2-oxo-6-[(4-phenyl-2-thiazolyl)carbonyl]-3-quinolinecarboxylate 406216-60-2P, Ethyl 4-(3-chlorophenyl)-1,2-dihydro-6-[hydroxy(4-phenyl-2-thiazolyl)methyl]-2-oxo-3-quinolinecarboxylate 406216-61-3P, Ethyl 4-(3-chlorophenyl)-6-[chloro(4-phenyl-2-thiazolyl)methyl]-1,2-dihydro-2-oxo-3-quinolinecarboxylate 406216-62-4P, 4-(3-Chlorophenyl)-6-[hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-2(1H)-quinolinone 406216-63-5P, 4-(3-Chlorophenyl)-6-[hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-1-methyl-2(1H)-quinolinone 406216-64-6P, 4-(3-Chlorophenyl)-α-(3-furanyl)-2-methoxy-6-quinolinemethanol 406216-65-7P, [4-(3-Chlorophenyl)-2-methoxy-6-quinolinyl]-3-furanylmethanone 406216-66-8P, 4-(3-Chlorophenyl)-6-(3-furanylcarbonyl)-2(1H)-quinolinone 406216-67-9P, 4-(3-Chlorophenyl)-6-(3-furanylcarbonyl)-1-methyl-2(1H)-quinolinone 406216-68-0P, 6-Bromo-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone 406216-69-1P, 4-(3-Chlorophenyl)-1-methyl-6-[(1-methyl-1H-imidazol-5-yl)carbonyl]-2(1H)-quinolinone 406216-73-7P, 4-(3-Chlorophenyl)-6-[methoxy(1-methyl-1H-imidazol-5-yl)-2-thiazolylmethyl]-1-methyl-2(1H)-quinolinone 406216-76-0P, Ethyl 4-(3-chlorophenyl)-1,2-dihydro-2-oxo-6-[(2-phenyl-1H-imidazol-1-yl)(4-phenyl-2-thiazolyl)methyl]-3-quinolinecarboxylate 406216-77-1P, 4-(3-Chlorophenyl)-3-(hydroxymethyl)-6-[(2-phenyl-1H-imidazol-1-yl)(4-phenyl-2-thiazolyl)methyl]-2(1H)-quinolinone 406216-82-8P, 6-[Chloro(3-furanyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of quinolinone derivs. as ***farnesyl*** transferase inhibitors for treatment of tumors and proliferative

diseases)
IT 131384-38-8, Protein ***farnesyl*** transferase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of quinoline derivs. as ***farnesyl*** transferase inhibitors for treatment of tumors and proliferative diseases)
IT 51-17-2, Benzimidazole 288-47-1, Thiazole 498-60-2, 3-Furancarboxaldehyde 586-78-7, 1-Bromo-4-nitrobenzene 616-47-7, 1-Methyl-1H-imidazole 670-96-2, 2-Phenyl-1H-imidazole 1529-41-5, 3-Chlorobenzeneacetonitrile 1826-12-6, 4-Phenylthiazole 2403-53-4, 2-(4-Nitrophenyl)-1,3-dioxolane 36239-09-5, 3-Chloro-3-oxopropanoic acid ethyl ester 39021-62-0, 1-Methyl-1H-imidazole-5-carboxaldehyde 147716-03-8, 1-Methyl-5-(tributylstannyl)-1H-imidazole 406216-47-5, Bis(1-methyl-1H-imidazol-5-yl)methanone
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of quinolinone derivs. as ***farnesyl*** transferase inhibitors for treatment of tumors and proliferative diseases)
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:240763 CAPLUS Full-text
DOCUMENT NUMBER: 136:279471
TITLE: Preparation of 6-heterocyclylmethyl quinoline and ***quinazoline*** derivatives as ***farnesyl*** transferase inhibitors for treatment of tumors and proliferative diseases
INVENTOR(S): ***Angibaud, Patrick Rene***; Venet, Marc Gaston; Mevellec, Laurence Anne
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2002024686 | A2 | 20020328 | WO 2001-EP10894 | 20010918 |
| WO 2002024686 | A3 | 20020613 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2002020559 | A5 | 20020402 | AU 2002-20559 | 20010918 |
| EP 1322650 | A2 | 20030702 | EP 2001-985254 | 20010918 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| JP 2004509887 | T | 20040402 | JP 2002-529096 | 20010918 |
| US 2003207887 | A1 | 20031106 | US 2003-381361 | 20030324 |

| | | | |
|---|---|---|---|
| PRIORITY APPLN. INFO.: | EP 2000-203368 | A | 20000925 |
| | EP 2001-202190 | A | 20010607 |
| | WO 2001-EP10894 | W | 20010918 |

OTHER SOURCE(S): MARPAT 136:279471

GI



I



II

AB Title compds. I [wherein m = independently 0-5; q = 0-3; Y1Y2 = C:N, C:CR9, CHNR9, or CHCHR9; C9 = H, halo, CN, (cyclo)alkyl, hydroxyalkyl, alkoxy(alkyl), aminoalkyl, (amino)alkenyl, (amino)alkynyl, halocarbonyl, hydroxycarbonyl, alkoxycarbonyl, aryl, (un)substituted amino or carbamoyl, etc.; R1 = azido, OH, halo, CN, NO2, trihalomethyl, alkoxy, aryloxy, heterocyclyloxy, alkylthio, or (un)substituted (cyclo)alkyl, alkenyl, alkynyl, carbamoyl, amino, sulfamoyl, etc.; or 2 adjacent R1 = OCH2O, OCH2CH2O, OCH:CH, OCH2CH2, OCH2CH2CH2, CH:CHCH:CH; R2 = (un)substituted mono- or bicyclic heterocyclic ring; R3 = H, halo, CN, alkenyl, alkynyl, hydroxycarbonyl, alkoxycarbonyl, aryl, heterocyclyl, alkoxy, alkylthio, (un)substituted (cyclo)alkyl or amino, etc.; R4 = (un)substituted imidazolyl, ***triazolyl***, or pyridyl; R5 = CN, OH, halo, alkenyl, alkynyl, hydroxycarbonyl, alkoxycarbonyl, or (un)substituted (cyclo)alkyl, alkoxy, amino, or carbamoyl, etc.; R6 = halo or (un)substituted (cyclo)alkyl, alkenyl, alkynyl, alkylthio, carboxy, carbamoyl, acyl(amino), etc.; R7 = O or S; or R6R7 = (un)substituted CH:CHN:, CH:NN:, CONHN:, N;NN:, N:CHN:, CH:CHCH:, CH:NCH:, CONHCH:, N:NCH:, or CH2(CH2)0-1CH2N: ; or pharmaceutically acceptable salts, N-oxides, or stereochem. isomeric forms thereof] were prepared For example, 2,2,2-trichloro-N-[2-(3-chlorobenzoyl)-4-[(5-chloro-2- thienyl)carbonyl]phenyl]acetamide (5-step preparation given) was cyclized with ammonium acetate in DMSO to give 4-(3-chlorophenyl)-6-[(5-chloro-2- thienyl)carbonyl]-2(1H)-***quinazolinone*** (83.8%). Chlorination (88.4%), followed by addition of 1-methyl-1H-imidazole in the presence of BuLi and SiEt3Cl in THF, afforded the α-(1-methyl-1H-imidazol-5-yl)- 6-***quinazolinemethanol***. Cycloaddn. with NaN3 in DMF gave the tetrazolo[1,5-a]***quinazoline***-7-methanol II (66%). I have potent ***farnesyl*** transferase inhibitory effect and are useful for inhibiting proliferative diseases and growth of tumors expressing an activated ras oncogene (no data).

IC ICM C07D409-14

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1

ST ***quinazoline*** quinoline prepn ***farnesyl*** transferase inhibitor; quinoline ***quinazoline*** prepn antitumor antiproliferative

IT Antitumor agents
Cytotoxic agents
(preparation of quinoline and ***quinazoline*** derivs. as ***farnesyl*** transferase inhibitors for treatment of tumors and proliferative diseases)

IT Ras proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of quinoline and ***quinazoline*** derivs. as

***farnesyl*** transferase inhibitors for treatment of tumors and proliferative diseases)

IT 406197-03-3P, 5-(3-Chlorophenyl)-α-(3-furanyl)-α-(1-methyl-1H-imidazol-5-yl)tetrazolo[1,5-a]quinoline-7-methanol
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(***farnesyl*** transferase inhibitor; preparation of quinoline and ***quinazoline*** derivs. as ***farnesyl*** transferase inhibitors for treatment of tumors and proliferative diseases)

IT 406196-99-4P, 5-(3-Chlorophenyl)-α-(5-chloro-2-thienyl)-α-(1-methyl-1H-imidazol-5-yl)tetrazolo[1,5-a]***quinazoline***-7-methanol
406197-02-2P, 4-(3-Chlorophenyl)-6-[(5-chloro-2-thienyl)hydroxy(4-methyl-4H-1,2,4-***triazol***-3-yl)methyl]-1-methyl-2(1H)-quinolinone
406197-06-6P, 5-(3-Chlorophenyl)-α-(3-furanyl)-α-(1-methyl-1H-imidazol-5-yl)tetrazolo[1,5-a]quinoline-7-methanamine 406197-10-2P, 4-(3-Chlorophenyl)-6-[hydroxy(1-methyl-1H-imidazol-5-yl)-6-quinolinylmethyl]-1-methyl-2(1H)-***quinazolinone*** 406197-11-3P, 4-(3-Chlorophenyl)-6-[(5-chloro-2-thienyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-2(1H)-***quinazolinone*** 406197-12-4P, 4-(3-Chlorophenyl)-6-[(6-chloro-3-pyridinyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-2(1H)-***quinazolinone*** 406197-13-5P, 5-(3-Chlorophenyl)-7-[(1-methyl-1H-imidazol-5-yl)(2-phenyl-1H-imidazol-1-yl)methyl]tetrazolo[1,5-a]***quinazoline*** 406197-14-6P, 5-(3-Chlorophenyl)-α-(5-chloro-2-thienyl)-α-(1-methyl-1H-imidazol-5-yl)tetrazolo[1,5-a]quinoline-7-methanol 406197-15-7P, 5-(3-Chlorophenyl)-α-(3-furanyl)-α-(1-methyl-1H-imidazol-5-yl)tetrazolo-[1,5-a]***quinazoline***-7-methanol 406197-16-8P, 5-(3-Chlorophenyl)-α-(1-methyl-1H-imidazol-5-yl)-α-(6-quinolinyl)tetrazolo-[1,5-a]***quinazoline***-7-methanol
406197-17-9P, 5-(3-Chlorophenyl)-α-(6-chloro-3-pyridinyl)-α-(1-methyl-1H-imidazol-5-yl)tetrazolo[1,5-a]quinoline-7-methanol
406197-18-0P, 5-(3-Chlorophenyl)-α-(5-chloro-2-thienyl)-α-(1-methyl-1H-imidazol-5-yl)tetrazolo[1,5-a]quinoline-7-methanamine
406197-19-1P, 5-(3-Chlorophenyl)-α-(5-chloro-2-thienyl)-α-(1-methyl-1H-imidazol-5-yl)tetrazolo[1,5-a]***quinazoline***-7-methanamine 406197-21-5P, α-(2-Benzofuranyl)-5-(3-chlorophenyl)-α-(1-methyl-1H-imidazol-5-yl)tetrazolo[1,5-a]quinoline-7-methanamine
406197-22-6P, 5-(3-Chlorophenyl)-α-(6-chloro-3-pyridinyl)-α-(1-methyl-1H-imidazol-5-yl)tetrazolo[1,5-a]quinoline-7-methanamine
406197-23-7P, 4-(3-Chlorophenyl)-6-[(5-chloro-2-thienyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-1-methyl-2(1H)-***quinazolinone***
406197-24-8P, 5-(3-Chlorophenyl)-α-(1-methyl-1H-imidazol-5-yl)-α-(5-methyl-2-thienyl)tetrazolo[1,5-a]quinoline-7-methanol
406197-26-0P, α-(2-Benzofuranyl)-5-(3-chlorophenyl)-α-(1-methyl-1H-imidazol-5-yl)tetrazolo[1,5-a]***quinazoline***-7-methanamine 406197-28-2P, 5-(3-Chlorophenyl)-7-[(2-ethyl-1H-imidazol-1-yl)(1-methyl-1H-imidazol-5-yl)methyl]tetrazolo[1,5-a]***quinazoline***
406197-29-3P, 5-(3-Chlorophenyl)-α,α-bis(1-methyl-1H-imidazol-5-yl)tetrazolo-[1,5-a]***quinazoline***-7-methanol 406197-30-6P, 5-(3-Chlorophenyl)-7-[[2-(4-fluorophenyl)-1H-imidazol-1-yl](1-methyl-1H-imidazol-5-yl)methyl]tetrazolo[1,5-a]***quinazoline*** 406197-31-7P, α-(Benzo[b]thien-2-yl)-5-(3-chlorophenyl)-α-(1-methyl-1H-imidazol-5-yl)tetrazolo[1,5-a]quinoline-7-methanamine 406197-32-8P, 5-(3-Chlorophenyl)-7-[(1-methyl-1H-imidazol-5-yl)(2-phenyl-1H-imidazol-1-yl)methyl]tetrazolo[1,5-a]quinoline 406197-33-9P, 5-(3-Chlorophenyl)-7-[[2-(2-chlorophenyl)-1H-imidazol-1-yl](1-methyl-1H-imidazol-5-

yl)methyl]tetrazolo[1,5-a]quinoline 406197-35-1P, 3-[1-[[5-(3-Chlorophenyl)tetrazolo[1,5-a]***quinazolin***-7-yl](1-methyl-1H-imidazol-5-yl)methyl]-1H-imidazol-2-yl]benzonitrile 406197-36-2P, 5-(3-Chlorophenyl)-7-[(2-ethyl-1H-imidazol-1-yl)(1-methyl-1H-imidazol-5-yl)methyl]tetrazolo[1,5-a]quinoline 406197-38-4P 406197-40-8P 406197-41-9P 406197-42-0P 406197-44-2P 406197-45-3P 406197-46-4P 406197-50-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(***farnesyl*** transferase inhibitor; preparation of quinoline and ***quinazoline*** derivs. as ***farnesyl*** transferase inhibitors for treatment of tumors and proliferative diseases)

IT 65247-25-8P, (2-Amino-5-bromophenyl)(3-chlorophenyl)methanone 190898-86-3P, 6-Bromo-4-(3-chlorophenyl)-2-methoxyquinoline 280143-23-9P, 6-Bromo-2-chloro-4-(3-chlorophenyl)quinoline 288391-74-2P, 6-Bromo-4-(3-chlorophenyl)-2(1H)-quinolinone 288391-98-0P, [4-(3-Chlorophenyl)-2-methoxy-6-quinolinyl](5-chloro-2-thienyl)methanone 288391-99-1P, 4-(3-Chlorophenyl)-6-[(5-chloro-2-thienyl)carbonyl]-2(1H)-quinolinone 288392-00-7P, 4-(3-Chlorophenyl)-6-[(5-chloro-2-thienyl)carbonyl]-1-methyl-2(1H)-quinolinone 406161-71-5P, 5-Bromo-3-(3-chlorophenyl)-2,1-benzisoxazole 406161-72-6P, N-[4-Bromo-2-(3-chlorobenzoyl)phenyl]acetamide 406161-78-2P, 4-(3-Chlorophenyl)-2-methoxy-6-quinolinecarboxaldehyde 406196-63-2P, [3-(3-Chlorophenyl)-2,1-benzisoxazol-5-yl](5-chloro-2-thienyl)methanone 406196-65-4P, [4-Amino-3-(3-chlorobenzoyl)phenyl](5-chloro-2-thienyl)methanone 406196-67-6P, 2,2,2-Trichloro-N-[2-(3-chlorobenzoyl)-4-[(5-chloro-2-thienyl)carbonyl]phenyl]acetamide 406196-68-7P, 4-(3-Chlorophenyl)-6-[(5-chloro-2-thienyl)carbonyl]-2(1H)-***quinazolinone*** 406196-69-8P, [2-Chloro-4-(3-chlorophenyl)-6-***quinazolinyl***](5-chloro-2-thienyl)methanone 406196-70-1P, 2-Chloro-4-(3-chlorophenyl)-α-(5-chloro-2-thienyl)-α-(1-methyl-1H-imidazol-5-yl)-6-***quinazolinemethanol*** 406196-72-3P, 4-(3-Chlorophenyl)-α-(5-chloro-2-thienyl)-2-methoxy-6-quinolinemethanol 406196-74-5P 406196-76-7P, 2-Chloro-4-(3-chlorophenyl)-α-(3-furanyl)-6-quinolinemethanol 406196-77-8P, [2-Chloro-4-(3-chlorophenyl)-6-quinolinyl]-3-furanylmethanone 406196-78-9P, 2-Chloro-4-(3-chlorophenyl)-α-(3-furanyl)-α-(1-methyl-1H-imidazol-5-yl)-6-quinolinemethanol 406196-80-3P, α-[3-(3-Chlorophenyl)-2,1-benzisoxazol-5-yl]-6-quinolinemethanol 406196-81-4P, [3-(3-Chlorophenyl)-2,1-benzisoxazol-5-yl]-6-quinolinylmethanone 406196-82-5P, [4-Amino-3-(3-chlorobenzoyl)phenyl]-6-quinolinylmethanone 406196-83-6P, 2,2,2-Trichloro-N-[2-(3-chlorobenzoyl)-4-(6-quinolinylcarbonyl)phenyl]acetamide 406196-84-7P, 4-(3-Chlorophenyl)-6-(6-quinolinylcarbonyl)-2(1H)-***quinazolinone*** 406196-85-8P, [2-Chloro-4-(3-chlorophenyl)-6-***quinazolinyl***]-6-quinolinylmethanone 406196-86-9P, 2-Chloro-4-(3-chlorophenyl)-α-(1-methyl-1H-imidazol-5-yl)-α-(6-quinolinyl)-6-***quinazolinemethanol*** 406196-87-0P, 3-(3-Chlorophenyl)-α-(6-chloro-3-pyridinyl)-α-(1-methyl-1H-imidazol-5-yl)-2,1-benzisoxazole-5-methanol 406196-88-1P, [2-Amino-5-[(6-chloro-3-pyridinyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]phenyl](3-chlorophenyl)methanone 406196-89-2P, 2,2,2-Trichloro-N-[2-(3-chlorobenzoyl)-4-[(6-chloro-3-pyridinyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]phenyl]acetamide 406196-90-5P, N-[4-Bromo-2-(3-chlorobenzoyl)phenyl]-2,2,2-trichloroacetamide 406196-91-6P, 6-Bromo-4-(3-chlorophenyl)-2(1H)-***quinazolinone*** 406196-92-7P, 6-Bromo-2-chloro-4-(3-chlorophenyl)***quinazoline*** 406196-93-8P, 4-(3-Chlorophenyl)-N,2-dimethoxy-N-methyl-6-***quinazolinecarboxamide*** 406196-94-9P,

2-Chloro-4-(3-chlorophenyl)-N-methoxy-N-methyl-6-***quinazolinecarboxamide*** 406196-95-0P, [2-Chloro-4-(3-chlorophenyl)-6-***quinazolinyl***](1-methyl-1H-imidazol-5-yl)methanone 406196-96-1P, 2-Chloro-4-(3-chlorophenyl)-α-(1-methyl-1H-imidazol-5-yl)-6-***quinazolinemethanol*** 406196-97-2P, 5-(3-Chlorophenyl)-α-(1-methyl-1H-imidazol-5-yl)tetrazolo[1,5-a]***quinazoline***-7-methanol 406197-04-4P, 7-[Chloro-3-furanyl(1-methyl-1H-imidazol-5-yl)methyl]-5-(3-chlorophenyl)tetrazolo[1,5-a]quinoline 406197-08-8P, 4-(3-Chlorophenyl)-6-[hydroxy(1-methyl-1H-imidazol-5-yl)-6-quinolinylmethyl]-2(1H)-***quinazolinone***
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of quinoline and ***quinazoline*** derivs. as ***farnesyl*** transferase inhibitors for treatment of tumors and proliferative diseases)

IT 131384-38-8, Protein ***farnesyl*** transferase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of quinoline and ***quinazoline*** derivs. as ***farnesyl*** transferase inhibitors for treatment of tumors and proliferative diseases)

IT 96-43-5, 2-Chlorothiophene 498-60-2, 3-Furancarboxaldehyde 586-78-7, 1-Bromo-4-nitrobenzene 616-47-7, 1-Methyl-1H-imidazole 670-96-2, 2-Phenyl-1H-imidazole 1529-41-5, 3-Chlorobenzeneacetonitrile 4113-04-6, 6-Quinolinecarboxaldehyde 7283-96-7, 5-Chloro-2-thiophenecarboxaldehyde 24854-43-1, 2,4-Dihydro-4-methyl-3H-1,2,4-***triazole***-3-thione 288392-09-6, (6-Chloro-3-pyridinyl)(1-methyl-1H-imidazol-5-yl)methanone 406197-01-1, 7-[Chloro(1-methyl-1H-imidazol-5-yl)methyl]-5-(3-chlorophenyl)tetrazolo[1,5-a]***quinazoline*** hydrochloride
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of quinoline and ***quinazoline*** derivs. as ***farnesyl*** transferase inhibitors for treatment of tumors and proliferative diseases)

L25 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:240760 CAPLUS Full-text
DOCUMENT NUMBER: 136:279470
TITLE: Preparation of 6-[(substituted phenyl)methyl]quinoline and ***quinazoline*** derivatives as ***farnesyl*** transferase inhibitors for treatment of tumors and proliferative diseases
INVENTOR(S): ***Angibaud, Patrick Rene***; Venet, Marc Gaston; Saha, Ashis Kumar; Mevellec, Laurence Anne
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 97 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2002024683 | A1 | 20020328 | WO 2001-EP10895 | 20010918 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

| | | | | | |
|---|---|---|---|---|---|
| AU 200193829 | A | 20020402 | AU 2001-93829 | | 20010918 |
| EP 1322636 | A1 | 20030702 | EP 2001-974276 | | 20010918 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | | |
| JP 2004509884 | T | 20040402 | JP 2002-529093 | | 20010918 |
| US 2004048882 | A1 | 20040311 | US 2003-381556 | | 20030324 |
| US 7173040 | B2 | 20070206 | | | |
| PRIORITY APPLN. INFO.: | | | EP 2000-203366 | A | 20000925 |
| | | | WO 2001-EP10895 | W | 20010918 |

OTHER SOURCE(S): MARPAT 136:279470

GI




I




II

AB Title compds. I [wherein m and n = independently 0-5; q = 0-3; Y1Y2 = C:N, C:CR9, CHNR9, or CHCHR9; C9 = H, halo, CN, (cyclo)alkyl, hydroxyalkyl, alkoxy(alkyl), aminoalkyl, (amino)alkenyl, (amino)alkynyl, halocarbonyl, hydroxycarbonyl, alkoxycarbonyl, aryl, (un)substituted amino or carbamoyl, etc.; R1 and R2 = independently azido, OH, halo, CN, NO2, trihalomethyl, alkoxy, aryloxy, heterocyclyloxy, alkylthio, or (un)substituted (cyclo)alkyl, alkenyl, alkynyl, carbamoyl, amino, sulfamoyl, etc.; or 2 adjacent R1 = OCH2O, OCH2CH2O, OCH:CH, OCH2CH2, OCH2CH2CH2, CH:CHCH:CH; R3 = H, halo, CN, alkenyl, alkynyl, hydroxycarbonyl, alkoxycarbonyl, aryl, heterocyclyl, alkoxy, alkylthio, (un)substituted (cyclo)alkyl or amino, etc.; R4 = (un)substituted imidazolyl, ***triazolyl***, or pyridyl; R5 = CN, OH, halo, alkenyl, alkynyl, hydroxycarbonyl, alkoxycarbonyl, or (un)substituted (cyclo)alkyl, alkoxy, amino, or carbamoyl, etc.; R6 = halo or (un)substituted (cyclo)alkyl, alkenyl, alkynyl, alkylthio, carboxy, carbamoyl, acyl(amino), etc.; R7 = O or S; or R6R7 = (un)substituted CH:CHN:, CH:NN:, CONHN:, N;NN:, N:CHN:, CH:CHCH:, CH:NCH:, CONHCH:, N:NCH:, or CH2(CH2)0-1CH2N: ; or pharmaceutically acceptable salts, N-oxides, or stereochem. isomeric forms thereof] were prepared For example, 6-bromo-2-chloro-4-(3-chlorophenyl)quinoline (6-step preparation given) was coupled with 4-(diethoxymethyl)benzaldehyde in the presence of BuLi in THF to give the 6-quinolinemethanol (64%), which was treated with MnO2 in 1,4-dioxane to afford the methanone. Methoxylation using MeONa in MeOH (74%), followed by addition of 1-methyl-1H-imidazole in the presence of BULi and ClSiEt3 in THF, gave 4-(3-chlorophenyl)-α-[4- (diethoxymethyl)phenyl]-2-methoxy-α-(1-methyl-1H-imidazol-5-yl)-6- quinolinemethanol (56%). The latter was refluxed in HCl for 24 h, cooled, poured out into H2O, and stirred at room temperature for 1 h to afford the quinolinone II•HCl (98%). I have potent ***farnesyl*** transferase inhibitory effect and are useful for inhibiting

proliferative diseases and growth of tumors expressing an activated ras oncogene (no data).

IC ICM C07D401-06
ICS A61K031-47; A61P043-00; C07D401-14; C07D487-04; C07D405-14; C07D403-06; C07D409-14; C07D413-14; C07D417-14; C07D487-04; C07D257-00; C07D239-00

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1

ST ***quinazoline*** quinoline prepn ***farnesyl*** transferase inhibitor; quinoline ***quinazoline*** prepn antitumor antiproliferative

IT Antitumor agents
Cytotoxic agents
(preparation of quinoline and ***quinazoline*** derivs. as ***farnesyl*** transferase inhibitors for treatment of tumors and proliferative diseases)

IT Ras proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of quinoline and ***quinazoline*** derivs. as ***farnesyl*** transferase inhibitors for treatment of tumors and proliferative diseases)

IT 406162-40-1P, 4-[[4-(3-Chlorophenyl)-1,2-dihydro-2-oxo-6-quinolinyl]hydroxy(1-methyl-1H-imidazol-5-yl)methyl]benzaldehyde monohydrochloride 406162-42-3P, 4-[[4-(3-Chlorophenyl)-1,2-dihydro-2-oxo-6-quinolinyl]hydroxy(1-methyl-1H-imidazol-5-yl)methyl]benzaldehyde oxime 406162-43-4P, 4-[[4-(3-Chlorophenyl)-1,2-dihydro-2-oxo-6-quinolinyl]hydroxy(1-methyl-1H-imidazol-5-yl)methyl]benzoic acid monohydrochloride 406162-44-5P, 4-(3-Chlorophenyl)-6-[hydroxy(1-methyl-1H-imidazol-5-yl)(4-nitrophenyl)methyl]-1-methyl-2(1H)-quinolinone 406162-46-7P, 4-[[4-(3-Chlorophenyl)-1,2-dihydro-1-methyl-2-oxo-6-quinolinyl]hydroxy(1-methyl-1H-imidazol-5-yl)methyl]benzaldehyde 406162-47-8P, 4-(3-Chlorophenyl)-6-[(4-chlorophenyl)(4-methyl-4H-1,2,4-***triazol***-3-yl)methyl]-1-methyl-2(1H)-quinolinone 406162-50-3P, 4-(3-Chlorophenyl)-6-[hydroxy[4-(hydroxymethyl)phenyl](1-methyl-1H-imidazol-5-yl)methyl]-1-methyl-2(1H)-quinolinone 406162-53-6P, 1-Methylethyl 4-[[4-(3-chlorophenyl)-1,2-dihydro-1-methyl-2-oxo-6-quinolinyl]hydroxy(1-methyl-1H-imidazol-5-yl)methyl]benzoate 406162-54-7P, 4-(3-Chlorophenyl)-6-[(4-chlorophenyl)hydroxy(4-methyl-4H-1,2,4-***triazol***-3-yl)methyl]-1-methyl-2(1H)-quinolinone 406162-55-8P, 6-[[4-(Chloromethyl)phenyl]hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone 406162-60-5P, 4-[[4-(3-Chlorophenyl)-1,2-dihydro-1-methyl-2-oxo-6-quinolinyl]hydroxy(1-methyl-1H-imidazol-5-yl)methyl]benzoic acid 406162-85-4P, 4-(3-Chlorophenyl)-6-[(4-chlorophenyl)hydroxy(4-methyl-4H-1,2,4-***triazol***-3-yl)methyl]-2(1H)-quinolinone 406162-90-1P, α-[5-(3-Chlorophenyl)tetrazolo[1,5-a]***quinazolin***-7-yl]-α-(1-methyl-1H-imidazol-5-yl)-1,4-benzenedimethanol 406162-93-4P, 4-(3-Chlorophenyl)-6-[(4-chlorophenyl)(4-chloro-3-pyridinyl)hydroxymethyl]-1-methyl-2(1H)-quinolinone 406162-95-6P 406163-00-6P, 6-[Amino[4-(aminomethyl)phenyl](1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(***farnesyl*** transferase inhibitor; preparation of quinoline and ***quinazoline*** derivs. as ***farnesyl*** transferase inhibitors for treatment of tumors and proliferative diseases)

IT 406162-41-2P, 4-[[4-(3-Chlorophenyl)-1,2-dihydro-2-oxo-6-quinolinyl]ethoxy(1-methyl-1H-imidazol-5-yl)methyl]benzaldehyde oxime 406162-45-6P, Methyl 4-[[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-6-

quinolinyl]hydroxy(1-methyl-1H-imidazol-5-yl)methyl]benzoate 406162-49-0P, 6-[Amino(1-methyl-1H-imidazol-5-yl)(4-nitrophenyl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone 406162-51-4P, 6-[(4'-Chloro[1,1'-biphenyl]-4-yl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone 406162-52-5P, 4-(3-Chlorophenyl)-6-[hydroxy[4-[[(2-methoxyethyl)amino]methyl]phenyl](1-methyl-1H-imidazol-5-yl)methyl]-1-methyl-2(1H)-quinolinone 406162-56-9P, 4-[[4-(3-Chlorophenyl)-1,2-dihydro-1-methyl-2-oxo-6-quinolinyl]hydroxy(1-methyl-1H-imidazol-5-yl)methyl]benzeneacetonitrile 406162-57-0P, 4-(3-Chlorophenyl)-6-[hydroxy[4-(methoxymethyl)phenyl](1-methyl-1H-imidazol-5-yl)methyl]-1-methyl-2(1H)-quinolinone 406162-58-1P, 4-(3-Chlorophenyl)-6-[hydroxy[4-(1-hydroxyethyl)phenyl](1-methyl-1H-imidazol-5-yl)methyl]-1-methyl-2(1H)-quinolinone 406162-59-2P, 4-(3-Chlorophenyl)-6-[hydroxy[4-(1H-imidazol-1-ylmethyl)phenyl](1-methyl-1H-imidazol-5-yl)methyl]-1-methyl-2(1H)-quinolinone 406162-61-6P, 5-(3-Chlorophenyl)-7-[(4-chlorophenyl)(4-methyl-4H-1,2,4-***triazol***-3-yl)methyl]tetrazolo[1,5-a]***quinazoline*** 406162-62-7P, 4-[[4-(3-Chlorophenyl)-1,2-dihydro-1-methyl-2-oxo-6-quinolinyl]hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-N-(3-pyridinyl)benzamide 406162-63-8P, 6-[Amino(4-chlorophenyl)(4-methyl-4H-1,2,4-***triazol***-3-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone 406162-64-9P, 4-(3-Chlorophenyl)-6-[hydroxy(1-methyl-1H-imidazol-5-yl)[4-(1H-tetrazol-1-ylmethyl)phenyl]methyl]-1-methyl-2(1H)-quinolinone 406162-65-0P, 4-(3-Chlorophenyl)-6-[[4-(ethoxymethyl)phenyl]hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-1-methyl-2(1H)-quinolinone 406162-66-1P, 4-(3-Chlorophenyl)-6-[hydroxy(1-methyl-1H-imidazol-5-yl)[4-[(2-thiazolylthio)methyl]phenyl]methyl]-1-methyl-2(1H)-quinolinone 406162-69-4P, 4-[[5-(3-Chlorophenyl)tetrazolo[1,5-a]***quinazolin***-7-yl](4-methyl-4H-1,2,4-***triazol***-3-yl)methyl]benzonitrile 406162-71-8P, 5-(3-Chlorophenyl)-α-(4-iodophenyl)-α-[4-methyl-5-(methylthio)-4H-1,2,4-***triazol***-3-yl]tetrazolo[1,5-a]***quinazoline***-7-methanol 406162-77-4P, 5-(3-Chlorophenyl)-α-(4-chlorophenyl)-α-(4-methyl-4H-1,2,4-***triazol***-3-yl)tetrazolo[1,5-a]***quinazoline***-7-methanamine 406162-82-1P, 4-[Amino[5-(3-chlorophenyl)tetrazolo[1,5-a]***quinazolin***-7-yl](4-methyl-4H-1,2,4-***triazol***-3-yl)methyl]benzonitrile 406162-83-2P, 4-(3-Chlorophenyl)-6-[(2,3-dihydro-1,4-benzodioxin-6-yl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-2(1H)-***quinazolinone*** 406162-84-3P, 6-[2-Chloro-1-(4-chlorophenyl)-1-(4-methyl-4H-1,2,4-***triazol***-3-yl)ethyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone 406162-86-5P, 4-[[4-(3-Chlorophenyl)-6-[(4-chlorophenyl)hydroxy(4-methyl-4H-1,2,4-***triazol***-3-yl)methyl]-2-oxo-1(2H)-quinolinyl]methyl]benzonitrile 406162-87-6P, 4-(3-Chlorophenyl)-6-[1-(4-chlorophenyl)-1-(4-methyl-4H-1,2,4-***triazol***-3-yl)ethyl]-1-methyl-2(1H)-quinolinone 406162-88-7P, 4-(3-Chlorophenyl)-6-[1-(4-chlorophenyl)-1-(4-methyl-4H-1,2,4-***triazol***-3-yl)ethyl]-1-methyl-2(1H)-quinolinone ethanedioate 406162-89-8P, Ethyl 5-(3-chlorophenyl)-7-[(4-chlorophenyl)(4-methyl-4H-1,2,4-***triazol***-3-yl)methyl]imidazo[1,2-a]quinoline-2-carboxylate 406162-91-2P, 6-[[4-[(Butylamino)methyl]phenyl]hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone 406162-92-3P, 4-[[5-(3-Chlorophenyl)tetrazolo[1,5-a]***quinazolin***-7-yl]hydroxy(1-methyl-1H-imidazol-5-yl)methyl]benzaldehyde 406162-96-7P, 6-[Amino(4-chlorophenyl)(4-methoxy-3-pyridinyl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone 406163-01-7P, 6-[(4-Amino-3-pyridinyl)(4-chlorophenyl)hydroxymethyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone 406163-02-8P, 4-(3-Chlorophenyl)-6-[(4-chlorophenyl)hydroxy(4-methyl-3-pyridinyl)methyl]-1-methyl-2(1H)-quinolinone 406163-03-9P, N-[[4-[Amino[4-(3-chlorophenyl)-1,2-dihydro-1-

methyl-2-oxo-6-quinolinyl](1-methyl-1H-imidazol-5-yl)methyl]phenyl]methyl]methanesulfonamide 406163-05-1P, 4-(3-Chlorophenyl)-6-[hydroxy[3-(hydroxymethyl)phenyl](1-methyl-1H-imidazol-5-yl)methyl]-1-methyl-2(1H)-quinolinone 406163-06-2P, 5-(3-Chlorophenyl)-4,5-dihydro-α-(4-iodophenyl)-α-(4-methyl-4H-1,2,4-***triazol***-3-yl)tetrazolo[1,5-a]***quinazoline***-7-methanol 406163-07-3P, 4-[[4-(3-Chlorophenyl)-1,2-dihydro-2-oxo-6-quinolinyl]hydroxy(1-methyl-1H-imidazol-5-yl)methyl]benzaldehyde 406163-08-4P, 4-[[4-(3-Chlorophenyl)-1,2-dihydro-1-methyl-2-oxo-6-quinolinyl]hydroxy(1-methyl-1H-imidazol-5-yl)methyl]benzaldehyde O-methyloxime 406163-09-5P, N-[[4-[[4-(3-Chlorophenyl)-1,2-dihydro-1-methyl-2-oxo-6-quinolinyl]hydroxy(1-methyl-1H-imidazol-5-yl)methyl]phenyl]methyl]phenylalanine methyl ester 406163-10-8P, 4-[[5-(3-Chlorophenyl)tetrazolo[1,5-a]***quinazolin***-7-yl]hydroxy(1-methyl-1H-imidazol-5-yl)methyl]benzeneacetonitrile
406163-11-9P 406163-12-0P 406163-13-1P 406163-14-2P 406163-15-3P
406163-16-4P 406163-17-5P 406163-18-6P 406163-19-7P 406163-20-0P
406163-21-1P 406163-22-2P 406163-23-3P 406163-24-4P 406163-25-5P
406163-26-6P 406163-27-7P 406163-28-8P 406163-29-9P 406163-30-2P
406163-31-3P 406163-32-4P 406163-33-5P 406163-34-6P 406163-35-7P
406163-36-8P 406163-37-9P 406163-38-0P 406163-39-1P 406163-40-4P
406163-41-5P 406163-42-6P 406163-43-7P 406163-44-8P 406163-45-9P
406163-46-0P 406163-47-1P 406163-48-2P 406163-49-3P 406163-50-6P
406163-51-7P 406163-52-8P 406163-53-9P 406163-54-0P 406163-55-1P
406163-56-2P 406163-57-3P 406163-58-4P 406163-59-5P 406163-60-8P
406163-61-9P 406163-62-0P 406163-63-1P 406163-64-2P 406163-65-3P
406163-66-4P 406163-67-5P 406163-68-6P 406163-69-7P 406163-70-0P
406163-71-1P 406163-72-2P 406163-73-3P 406163-74-4P 406163-75-5P
406163-76-6P 406163-77-7P 406163-78-8P 406163-79-9P 406163-80-2P
406163-82-4P 406163-83-5P 406163-84-6P 406163-85-7P 406163-86-8P
406163-87-9P 406163-88-0P 406163-89-1P 406163-90-4P 406163-91-5P
406163-92-6P 406163-93-7P 406163-94-8P 406163-95-9P 406163-96-0P
406163-97-1P 406163-98-2P 406163-99-3P 406164-00-9P 406164-01-0P
406164-02-1P 406164-03-2P 406164-04-3P 406164-05-4P 406164-06-5P
406164-07-6P 406164-08-7P 406164-09-8P 406164-10-1P 406164-11-2P
406164-12-3P 406164-13-4P 406164-14-5P 406164-15-6P 406164-16-7P
406164-17-8P 406164-18-9P 406164-19-0P 406164-20-3P 406164-21-4P
406164-22-5P 406164-23-6P 406164-24-7P 406164-25-8P 406164-26-9P
406164-27-0P 406164-28-1P 406164-29-2P 406164-30-5P 406164-31-6P
406164-32-7P 406164-33-8P 406164-34-9P 406164-35-0P 406164-36-1P
406164-37-2P 406164-38-3P 406164-39-4P 406164-40-7P 406164-41-8P
406164-42-9P 406164-43-0P 406164-44-1P 406164-45-2P 406164-46-3P
406164-47-4P 406164-48-5P 406164-49-6P 406164-50-9P 406164-51-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(***farnesyl*** transferase inhibitor; preparation of quinoline and ***quinazoline*** derivs. as ***farnesyl*** transferase inhibitors for treatment of tumors and proliferative diseases)

IT 65247-25-8P 190898-86-3P, 6-Bromo-4-(3-chlorophenyl)-2-methoxyquinoline 280143-19-3P 280143-23-9P, 6-Bromo-2-chloro-4-(3-chlorophenyl)quinoline 280144-86-7P, [2-Chloro-4-(3-chlorophenyl)-6-quinolinyl](4-chlorophenyl)methanone hydrochloride 288391-74-2P, 6-Bromo-4-(3-chlorophenyl)-2(1H)-quinolinone 406161-71-5P, 5-Bromo-3-(3-chlorophenyl)-2,1-benzisoxazole 406161-72-6P 406161-74-8P 406161-75-9P, [2-Chloro-4-(3-chlorophenyl)-6-quinolinyl] [4-(diethoxymethyl)phenyl]methanone 406161-76-0P, [4-(3-Chlorophenyl)-2-methoxy-6-quinolinyl][4-(diethoxymethyl)phenyl]methanone 406161-77-1P 406161-78-2P, 4-(3-Chlorophenyl)-2-methoxy-6-quinolinecarboxaldehyde 406161-79-3P, 4-(3-Chlorophenyl)-α-[4-(4,5-dihydro-4,4-dimethyl-2-

oxazolyl)phenyl]-2-methoxy-6-quinolinemethanol 406161-80-6P, [4-(3-Chlorophenyl)-2-methoxy-6-quinolinyl][4-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)phenyl]methanone 406161-81-7P, 4-(3-Chlorophenyl)-α-[4-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)phenyl]-2-methoxy-α-(1-methyl-1H-imidazol-5-yl)-6-quinolinemethanol 406161-82-8P, 4-(3-Chlorophenyl)-3,4-dihydro-6-(4-nitrobenzoyl)-2(1H)-quinolinone 406161-83-9P, 4-(3-Chlorophenyl)-6-(4-nitrobenzoyl)-2(1H)-quinolinone 406161-84-0P, 4-(3-Chlorophenyl)-1-methyl-6-(4-nitrobenzoyl)-2(1H)-quinolinone 406161-85-1P, [4-(3-Chlorophenyl)-2-methoxy-6-quinolinyl](4-iodophenyl)methanone 406161-86-2P, 4-(3-Chlorophenyl)-6-(4-iodobenzoyl)-2(1H)-quinolinone 406161-87-3P, 4-(3-Chlorophenyl)-6-(4-iodobenzoyl)-1-methyl-2(1H)-quinolinone 406161-88-4P, 4-(3-Chlorophenyl)-6-[hydroxy(4-iodophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-1-methyl-2(1H)-quinolinone 406161-89-5P 406161-90-8P 406161-91-9P 406161-92-0P 406161-93-1P 406161-94-2P 406161-95-3P 406161-96-4P 406161-97-5P 406161-98-6P 406161-99-7P 406162-00-3P, [3-(3-Chlorophenyl)-2,1-benzisoxazol-5-yl](4-iodophenyl)methanone 406162-01-4P, [4-Amino-3-(3-chlorobenzoyl)phenyl](4-iodophenyl)methanone 406162-02-5P, 2,2,2-Trichloro-N-[2-(3-chlorobenzoyl)-4-(4-iodobenzoyl)phenyl]acetamide 406162-03-6P, 4-(3-Chlorophenyl)-6-(4-iodobenzoyl)-2(1H)-***quinazolinone*** 406162-04-7P, [2-Chloro-4-(3-chlorophenyl)-6-***quinazolinyl***](4-iodophenyl)methanone 406162-05-8P, 2-Chloro-4-(3-chlorophenyl)-α-(4-iodophenyl)-6-***quinazolineacetonitrile*** 406162-06-9P, [4-(3-Chlorophenyl)-2-ethoxy-6-***quinazolinyl***](4-iodophenyl)methanone 406162-07-0P, 4-(3-Chlorophenyl)-2-hydrazino-α-(4-iodophenyl)-6-***quinazolineacetonitrile*** 406162-08-1P, 5-(3-Chlorophenyl)-α-(4-iodophenyl)tetrazolo[1,5-a]***quinazoline***-7-acetonitrile 406162-09-2P, Ethyl 5-(3-chlorophenyl)-α-(4-iodophenyl)tetrazolo[1,5-a]***quinazoline***-7-acetate 406162-10-5P, 5-(3-Chlorophenyl)-α-(4-iodophenyl)tetrazolo[1,5-a]***quinazoline***-7-acetic acid lithium salt 406162-11-6P, 2-[(Methylamino)thioxomethyl]hydrazide-5-(3-chlorophenyl)-α-(4-iodophenyl)tetrazolo[1,5-a]***quinazoline***-7-acetic acid 406162-12-7P, [5-(3-Chlorophenyl)tetrazolo[1,5-a]***quinazolin***-7-yl](4-iodophenyl)methanone 406162-13-8P, (4-Chlorophenyl)[5-(3-chlorophenyl)tetrazolo[1,5-a]***quinazolin***-7-yl]methanone 406162-14-9P, 3-(3-Chlorophenyl)-α-(2,3-dihydro-1,4-benzodioxin-6-yl)-2,1-benzisoxazole-5-methanol 406162-15-0P, [3-(3-Chlorophenyl)-2,1-benzisoxazol-5-yl](2,3-dihydro-1,4-benzodioxin-6-yl)methanone 406162-16-1P, [4-Amino-3-(3-chlorobenzoyl)phenyl](2,3-dihydro-1,4-benzodioxin-6-yl)methanone 406162-17-2P, 2,2,2-Trichloro-N-[2-(3-chlorobenzoyl)-4-[(2,3-dihydro-1,4-benzodioxin-6-yl)carbonyl]phenyl]acetamide 406162-18-3P, 4-(3-Chlorophenyl)-6-[(2,3-dihydro-1,4-benzodioxin-6-yl)carbonyl]-2(1H)-***quinazolinone*** 406162-19-4P, [2-Chloro-4-(3-chlorophenyl)-6-***quinazolinyl***](2,3-dihydro-1,4-benzodioxin-6-yl)methanone 406162-20-7P, 2-Chloro-4-(3-chlorophenyl)-α-(2,3-dihydro-1,4-benzodioxin-6-yl)-α-(1-methyl-1H-imidazol-5-yl)-6-***quinazolinemethanol*** 406162-21-8P, (4-Chlorophenyl)[4-(3-chlorophenyl)-2-methoxy-6-quinolinyl]methanone 406162-22-9P, 4-(3-Chlorophenyl)-α-(4-chlorophenyl)-α-(5-mercapto-4-methyl-4H-1,2,4-***triazol***-3-yl)-2-methoxy-6-quinolinemethanol 406162-23-0P, 4-(3-Chlorophenyl)-α-(4-chlorophenyl)-2-methoxy-α-(4-methyl-4H-1,2,4-***triazol***-3-yl)-6-quinolinemethanol 406162-24-1P, 5-(3-Chlorophenyl)-α-(4-chlorophenyl)tetrazolo[1,5-a]quinoline-7-acetonitrile 406162-25-2P, 5-(3-Chlorophenyl)-α-(4-chlorophenyl)tetrazolo[1,5-a]quinoline-7-acetic acid 406162-26-3P,

2-[(Methylamino)thioxomethyl]hydrazide-5-(3-chlorophenyl)-α-(4-chlorophenyl)tetrazolo[1,5-a]quinoline-7-acetic acid 406162-27-4P, 5-(3-Chlorophenyl)-7-[(4-chlorophenyl)[4-methyl-5-(methylthio)-4H-1,2,4-***triazol***-3-yl]methyl]tetrazolo[1,5-a]quinoline 406162-28-5P, 5-(3-Chlorophenyl)-7-[(4-chlorophenyl)(4-methyl-4H-1,2,4-***triazol***-3-yl)methyl]tetrazolo[1,5-a]quinoline 406162-29-6P, 4-(3-Chlorophenyl)-6-[(4-chlorophenyl)[4-methyl-5-(methylthio)-4H-1,2,4-***triazol***-3-yl]methyl]-2-quinolinamine 406162-30-9P, 4-(3-Chlorophenyl)-6-[(4-chlorophenyl)(4-methyl-4H-1,2,4-***triazol***-3-yl)methyl]-2-quinolinamine 406162-31-0P, 4-(3-Chlorophenyl)-2-ethoxy-α-(4-iodophenyl)-α-(1-methyl-1H-imidazol-5-yl)-6-***quinazolinemethanol*** 406162-32-1P, 1-Methylethyl 4-[[4-(3-chlorophenyl)-2-ethoxy-6-***quinazolinyl***]hydroxy(1-methyl-1H-imidazol-5-yl)methyl]benzoate 406162-33-2P, 1-Methylethyl 4-[[2-chloro-4-(3-chlorophenyl)-6-***quinazolinyl***]hydroxy(1-methyl-1H-imidazol-5-yl)methyl]benzoate 406162-34-3P, α-[2-Chloro-4-(3-chlorophenyl)-6-***quinazolinyl***]-α-(1-methyl-1H-imidazol-5-yl)-1,4-benzenedimethanol 406162-35-4P, N-[3-[(4-Chlorophenyl)[4-(3-chlorophenyl)-1,2-dihydro-1-methyl-2-oxo-6-quinolinyl]hydroxymethyl]-4-pyridinyl]-2,2-dimethylpropanamide 406162-36-5P, [4-(3-Chlorophenyl)-2-methoxy-6-quinolinyl](3-iodophenyl)methanone 406162-37-6P, 4-(3-Chlorophenyl)-6-(3-iodobenzoyl)-2(1H)-quinolinone 406162-38-7P, 4-(3-Chlorophenyl)-6-(3-iodobenzoyl)-1-methyl-2(1H)-quinolinone 406162-39-8P, 4-(3-Chlorophenyl)-6-[hydroxy(3-iodophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-1-methyl-2(1H)-quinolinone 406162-48-9P, 6-[Chloro(1-methyl-1H-imidazol-5-yl)(4-nitrophenyl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone monohydrochloride 406162-67-2P, 5-[[5-(3-Chlorophenyl)tetrazolo[1,5-a]***quinazolin***-7-yl](4-iodophenyl)methyl]-4-methyl-4H-1,2,4-***triazole***-3-thiol 406162-68-3P, 5-(3-Chlorophenyl)-7-[(4-iodophenyl)(4-methyl-4H-1,2,4-***triazol***-3-yl)methyl]tetrazolo[1,5-a]***quinazoline*** 406162-70-7P, 5-(3-Chlorophenyl)-α-(4-iodophenyl)-α-(5-mercapto-4-methyl-4H-1,2,4-***triazol***-3-yl)tetrazolo[1,5-a]***quinazoline***-7-methanol 406162-72-9P, 5-(3-Chlorophenyl)-α-(4-chlorophenyl)-α-(5-mercapto-4-methyl-4H-1,2,4-***triazol***-3-yl)tetrazolo[1,5-a]***quinazoline***-7-methanol 406162-73-0P, 5-(3-Chlorophenyl)-α-(4-chlorophenyl)-α-[4-methyl-5-(methylthio)-4H-1,2,4-***triazol***-3-yl]tetrazolo[1,5-a]***quinazoline***-7-methanol 406162-74-1P, 7-[Chloro(4-chlorophenyl)[4-methyl-5-(methylthio)-4H-1,2,4-***triazol***-3-yl]methyl]-5-(3-chlorophenyl)tetrazolo[1,5-a]***quinazoline*** monohydrochloride 406162-76-3P, 5-(3-Chlorophenyl)-α-(4-chlorophenyl)-α-[4-methyl-5-(methylthio)-4H-1,2,4-***triazol***-3-yl]tetrazolo[1,5-a]***quinazoline***-7-methanamine 406162-78-5P, 5-(3-Chlorophenyl)-α-(4-iodophenyl)-α-(4-methyl-4H-1,2,4-***triazol***-3-yl)tetrazolo[1,5-a]***quinazoline***-7-methanol 406162-79-6P, 7-[Chloro(4-iodophenyl)(4-methyl-4H-1,2,4-***triazol***-3-yl)methyl]-5-(3-chlorophenyl)tetrazolo[1,5-a]***quinazoline*** monohydrochloride 406162-81-0P, 5-(3-Chlorophenyl)-α-(4-iodophenyl)-α-(4-methyl-4H-1,2,4-***triazol***-3-yl)tetrazolo[1,5-a]***quinazoline***-7-methanamine 406162-94-5P, 6-[Chloro(4-chlorophenyl)(4-chloro-3-pyridinyl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone monohydrochloride 406162-97-8P, 4-[[4-(3-Chlorophenyl)-1,2-dihydro-2-oxo-6-quinolinyl]hydroxy(1-methyl-1H-imidazol-5-yl)methyl]benzonitrile 406162-98-9P, 4-[[4-(3-Chlorophenyl)-1,2-dihydro-1-methyl-2-oxo-6-quinolinyl]hydroxy(1-methyl-1H-imidazol-5-yl)methyl]benzonitrile 406162-99-0P, 4-[Amino[4-(3-chlorophenyl)-1,2-

dihydro-1-methyl-2-oxo-6-quinolinyl](1-methyl-1H-imidazol-5-yl)methyl]benzonitrile 406163-04-0P, 1-Methylethyl 3-[[4-(3-chlorophenyl)-1,2-dihydro-1-methyl-2-oxo-6-quinolinyl]hydroxy(1-methyl-1H-imidazol-5-yl)methyl]benzoate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of quinoline and ***quinazoline*** derivs. as ***farnesyl*** transferase inhibitors for treatment of tumors and proliferative diseases)

IT 131384-38-8, Protein ***farnesyl*** transferase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of quinoline and ***quinazoline*** derivs. as ***farnesyl*** transferase inhibitors for treatment of tumors and proliferative diseases)

IT 62-23-7, 4-Nitrobenzoic acid 109-73-9, 1-Butanamine, reactions 109-85-3, 2-Methoxyethanamine 288-32-4, 1H-Imidazole, reactions 288-94-8, 1H-Tetrazole 462-08-8, 3-Pyridinamine 586-78-7, 1-Bromo-4-nitrobenzene 616-47-7, 1-Methyl-1H-imidazole 1529-41-5, 3-Chlorobenzeneacetonitrile 1679-18-1, (4-Chlorophenyl)boronic acid 3430-22-6, 3-Bromo-4-methylpyridine 5685-05-2, 2(3H)-Thiazolethione 7379-35-3, 4-Chloropyridine hydrochloride 10564-55-3, 1-[(Isocyanomethyl)sulfonyl]-4-methylbenzene 17201-43-3, 4-(Bromomethyl)benzonitrile 24854-43-1, 2,4-Dihydro-4-methyl-3H-1,2,4-***triazole***-3-thione 29668-44-8, 2,3-Dihydro-1,4-benzodioxan-6-carboxaldehyde 32664-14-5, 2-(4-Bromophenyl)-4,5-dihydro-4,4-dimethyloxazole 70298-89-4, 2,2-Dimethyl-N-[4-pyridinyl]propanamide 81172-89-6, 4-(Diethoxymethyl)benzaldehyde 170282-53-8, 3-Iodo-N-methoxy-N-methylbenzamide 187617-01-2, 4-Iodo-N-methoxy-N-methylbenzamide 192187-30-7, 4-(3-Chlorophenyl)-3,4-dihydro-2(1H)-quinolinone 192187-32-9, 6-(4-Chlorobenzoyl)-4-(3-chlorophenyl)-2(1H)-quinolinone 192187-33-0, 6-(4-Chlorobenzoyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone 215034-82-5, 6-(4-Chlorobenzoyl)-4-(3-chlorophenyl)-2(1H)-***quinazolinone*** 280143-26-2, (4-Chlorophenyl)[5-(3-chlorophenyl)tetrazolo[1,5-a]quinolin-7-yl]methanone 406162-75-2, 7-[Chloro(4-chlorophenyl)[4-methyl-5-(methylthio)-4H-1,2,4-***triazol***-3-yl]methyl]-5-(3-chlorophenyl)tetrazolo[1,5-a]***quinazoline*** 406162-80-9, 7-[Chloro(4-iodophenyl)(4-methyl-4H-1,2,4-***triazol***-3-yl)methyl]-5-(3-chlorophenyl)tetrazolo[1,5-a]***quinazoline***
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of quinoline and ***quinazoline*** derivs. as ***farnesyl*** transferase inhibitors for treatment of tumors and proliferative diseases)

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:240759 CAPLUS Full-text
DOCUMENT NUMBER: 136:279469
TITLE: Preparation of quinoline and ***quinazoline*** derivatives as ***farnesyl*** transferase inhibitors for treatment of tumors and proliferative diseases
INVENTOR(S): ***Angibaud, Patrick Rene***; Venet, Marc Gaston; Pilatte, Isabelle Noeelle Constance
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2002024682 | A1 | 20020328 | WO 2001-EP10867 | 20010918 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| EP 1322635 | A1 | 20030702 | EP 2001-974271 | 20010918 |
| EP 1322635 | B1 | 20060322 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| JP 2004509883 | T | 20040402 | JP 2002-529092 | 20010918 |
| AT 321038 | T | 20060415 | AT 2001-974271 | 20010918 |
| ES 2261476 | T3 | 20061116 | ES 2001-1974271 | 20010918 |
| AU 200193826 | A | 20020402 | AU 2001-93826 | 20020402 |
| US 2003203904 | A1 | 20031030 | US 2003-381363 | 20030324 |
| US 7053105 | B2 | 20060530 | | |
| PRIORITY APPLN. INFO.: | | | EP 2000-203365 A | 20000925 |
| | | | WO 2001-EP10867 W | 20010918 |

OTHER SOURCE(S): MARPAT 136:279469

GI







II

AB Title compds. I [wherein m and n = independently 0-5; q = 0-3; Y1Y2 = C:N or C:CR9; C9 = H, halo, CN, (cyclo)alkyl, hydroxyalkyl, alkoxy(alkyl), aminoalkyl, (amino)alkenyl, (amino)alkynyl, halocarbonyl, hydroxycarbonyl, alkoxycarbonyl, aryl, (un)substituted amino or carbamoyl, etc.; R1 and R2= independently azido, OH, halo, CN, NO2, trihalomethyl, alkoxy, aryloxy, heterocyclyloxy, alkylthio, or (un)substituted (cyclo)alkyl, alkenyl, alkynyl, carbamoyl, amino, sulfamoyl, etc.; or R1R2 = OCH2O, OCH2CH2O, OCH:CH, OCH2CH2, OCH2CH2CH2, CH:CHCH:CH; R3 = H, halo, CN, alkenyl, alkynyl, hydroxycarbonyl, alkoxycarbonyl, aryl, heterocyclyl, alkoxy, alkylthio, (un)substituted (cyclo)alkyl or amino, etc.; R4 = (un)substituted imidazolyl, ***triazolyl***, or pyridyl; R5 = CN, OH, halo, alkenyl, alkynyl, hydroxycarbonyl, alkoxycarbonyl, or (un)substituted (cyclo)alkyl, alkoxy, amino, or carbamoyl, etc.; R7 = halo or (un)substituted (cyclo)alkyl, alkenyl, alkynyl, alkylthio, carboxy, carbamoyl, acyl(amino), etc.; or pharmaceutically acceptable salts, N-oxides,

or stereochem. isomeric forms thereof] were prepared For example, N-[2-(3-chlorobenzoyl)-4-(4-chlorobenzoyl)phenyl]acetamide was cyclized with NH3 in i-PrOH to give (4-chlorophenyl)[4-(3-chlorophenyl)-2-methyl-6-***quinazolinyl***]methanone (36%). Addition of 1-methyl-1H-imidazole in the presence of BuLi and SiEt3Cl in THF afforded II (40%). I have potent ***farnesyl*** transferase inhibitory effect and are useful for inhibiting proliferative diseases and growth of tumors expressing an activated ras oncogene (no data).

IC ICM C07D401-06
ICS A61K031-47; A61P043-00; C07D405-14; C07D409-14; C07D401-14; C07D417-14; C07D403-06

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1

ST ***quinazoline*** quinoline prepn ***farnesyl*** transferase inhibitor; quinoline ***quinazoline*** prepn antitumor antiproliferative

IT Antitumor agents
Cytotoxic agents
(preparation of quinoline and ***quinazoline*** derivs. as ***farnesyl*** transferase inhibitors for treatment of tumors and proliferative diseases)

IT Ras proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of quinoline and ***quinazoline*** derivs. as ***farnesyl*** transferase inhibitors for treatment of tumors and proliferative diseases)

IT 405548-83-6P, (E)-3-[4-(3-Chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-2-quinolinyl]-2-propenenitrile 405548-95-0P, 4-(3-Chlorophenyl)-α-(4-chlorophenyl)-2-methyl-α-[4-methyl-5-(methylthio)-4H-1,2,4-***triazol***-3-yl]-6-quinolinemethanol 405548-97-2P, 4-(3-Chlorophenyl)-α-(4-chlorophenyl)-2-methyl-α-[4-methyl-5-(methylthio)-4H-1,2,4-***triazol***-3-yl]-6-quinolinemethanamine 405549-01-1P, 2-Amino-4-(3-chlorophenyl)-α-(4-chlorophenyl)-α-(1-methyl-1H-imidazol-5-yl)-6-***quinazolinemethanol***
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(***farnesyl*** transferase inhibitor; preparation of quinoline and ***quinazoline*** derivs. as ***farnesyl*** transferase inhibitors for treatment of tumors and proliferative diseases)

IT 405548-81-4P, 4-(3-Chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-2-quinolinecarboxaldehyde oxime 405548-82-5P, Ethyl (E)-3-[4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-2-quinolinyl]propenoate 405548-84-7P, 4-(3-Chlorophenyl)-α-(4-chlorophenyl)-2-[[[2-(diethylamino)ethyl]amino]methyl]-α-(1-methyl-1H-imidazol-5-yl)-6-quinolinemethanol 405548-85-8P, 4-(3-Chlorophenyl)-α-(4-chlorophenyl)-2-(1-ethoxyethenyl)-α-(1-methyl-1H-imidazol-5-yl)-6-quinolinemethanol 405548-86-9P, 4-(3-Chlorophenyl)-α-(4-chlorophenyl)-α,2-bis(1-methyl-1H-imidazol-5-yl)-6-***quinazolinemethanol*** 405548-87-0P, 4-(3-Chlorophenyl)-6-[(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-N-[2-(dimethylamino)ethyl]-2-quinolinecarboxamide 405548-88-1P, N-[4-(3-Chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-2-quinolinyl]-2-furancarboxamide 405548-89-2P, N-[4-(3-Chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-2-quinolinyl]-N'-phenylurea 405548-90-5P, 4-Bromo-N-[4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-2-

quinolinyl]benzamide 405548-91-6P, (E)-3-[4-(3-Chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-2-quinolinyl]-2-propenamide 405548-92-7P, 1-Methylethyl 4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-2-***quinazolinecarboxylate*** 405548-93-8P, 4-(3-Chlorophenyl)-α-(4-chlorophenyl)-2-methyl-α-(1-methyl-1H-imidazol-5-yl)-6-***quinazolinemethanol*** 405548-96-1P, 4-(3-Chlorophenyl)-α-(4-chlorophenyl)-2-methyl-α-(4-methyl-4H-1,2,4-***triazol***-3-yl)-6-quinolinemethanol 405548-98-3P, 4-(3-Chlorophenyl)-α-(4-chlorophenyl)-2-methyl-α-(4-methyl-4H-1,2,4-***triazol***-3-yl)-6-quinolinemethanamine 405549-00-0P, α-(4-Chlorophenyl)-2-[(2-hydroxyethyl)amino]-α-(1-methyl-1H-imidazol-5-yl)-4-(3-methylphenyl)-6-quinolinemethanol 405549-02-2P, Ethyl [[4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-2-***quinazolinyl***]hydrazono]-(2E)-ethanoate 405549-03-3P, N-[4-(3-Chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-2-***quinazolinyl***]-N'-(2-methoxyethyl)thiourea 405549-04-4P, N-[4-(3-Chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-2-***quinazolinyl***]-N'-(1-methylethyl)urea 405549-05-5P, N-[4-(3-Chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-2-***quinazolinyl***]cyclohexanecarboxamide 405549-06-6P, 4-(3-Chlorophenyl)-6-[(4-chlorophenyl)-3-pyridinylmethyl]-N-(2-propenyl)-2-quinolinemethanamine 405549-07-7P, 4-(3-Chlorophenyl)-α-(4-chlorophenyl)-α-(1-methyl-1H-imidazol-5-yl)-2-(phenylethynyl)-6-quinolinemethanol 405549-08-8P, 4-(3-Chlorophenyl)-α-(4-chlorophenyl)-α-(1-methyl-1H-imidazol-5-yl)-2-(3-pyridinyl)-6-***quinazolinemethanol*** 405549-09-9P, 4-(3-Chlorophenyl)-α-(4-chlorophenyl)-α-(1-methyl-1H-imidazol-5-yl)-2-[(2-propenylamino)methyl]-6-quinolinemethanol 405549-10-2P 405549-11-3P, 4-(3-Chlorophenyl)-α-(4-chlorophenyl)-α-(1-methyl-1H-imidazol-5-yl)-2-[[[2-(1-pyrrolidinyl)ethyl]amino]methyl]-6-quinolinemethanol 405549-12-4P 405549-13-5P 405549-14-6P 405549-15-7P 405549-16-8P 405549-17-9P 405549-18-0P 405549-19-1P 405549-20-4P 405549-21-5P 405549-22-6P 405549-23-7P 405549-24-8P 405549-25-9P 405549-26-0P, 4-(3-Chlorophenyl)-6-[(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-N-(2-propenyl)-2-quinolinecarboxamide 405549-27-1P, 4-(3-Chlorophenyl)-6-[(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-N-[2-(4-morpholinyl)ethyl]-2-quinolinecarboxamide 405549-28-2P, Ethyl 4-[[[4-(3-chlorophenyl)-6-[(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-2-quinolinyl]carbonyl]amino]-1-piperidinecarboxylate 405549-29-3P, 1-[4-(3-Chlorophenyl)-6-[(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-2-quinolinylcarbonyl]piperidine 405549-30-6P, 1-[4-(3-Chlorophenyl)-6-[(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-2-quinolinecarbonyl]-4-methylpiperazine 405549-31-7P, 4-(3-Chlorophenyl)-6-[(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-N-(2-furanylmethyl)-2-quinolinecarboxamide 405549-32-8P 405549-33-9P 405549-34-0P, 4-(3-Chlorophenyl)-6-[(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-N-cyclopropyl-2-quinolinecarboxamide 405549-35-1P 405549-36-2P, 4-(3-Chlorophenyl)-6-[(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-N-[2-(1-pyrrolidinyl)ethyl]-2-quinolinecarboxamide 405549-37-3P 405549-38-4P 405549-39-5P 405549-40-8P 405549-41-9P 405549-42-0P 405549-43-1P 405549-44-2P 405549-45-3P 405549-46-4P 405549-47-5P 405549-48-6P 405549-49-7P 405549-50-0P 405549-51-1P 405549-52-2P 405549-53-3P 405549-54-4P 405549-55-5P 405549-56-6P 405549-57-7P 405549-58-8P 405549-59-9P 405549-61-3P, 4-(3-Chlorophenyl)-6-[(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-N-(4-pyridinylmethyl)-2-quinolinecarboxamide 405549-63-5P 405549-65-7P

405549-69-1P 405549-71-5P 405549-73-7P 405549-75-9P 405549-77-1P
405549-79-3P 405549-81-7P 405549-82-8P 405549-83-9P 405549-84-0P
405549-85-1P 405549-86-2P 405549-87-3P 405549-88-4P 405549-89-5P
405549-90-8P 405549-91-9P 405549-92-0P 405549-93-1P 405549-94-2P
405549-95-3P 405549-96-4P 405549-97-5P 405549-98-6P 405549-99-7P
405550-00-7P 405550-01-8P 405550-02-9P 405550-03-0P 405550-04-1P
405550-05-2P 405550-07-4P 405550-08-5P 405550-09-6P 405550-10-9P
405550-11-0P 405550-12-1P 405550-13-2P 405550-14-3P 405550-15-4P
405550-16-5P 405550-17-6P 405550-18-7P 405550-19-8P 405550-20-1P
405550-21-2P 405550-22-3P 405550-23-4P 405550-24-5P 405550-25-6P
405550-26-7P 405550-27-8P 405550-28-9P 405550-29-0P 405550-30-3P
405550-31-4P 405550-32-5P 405550-33-6P 405550-34-7P 405550-36-9P
405550-38-1P 405550-40-5P 405550-42-7P 405550-44-9P 405550-45-0P
405550-47-2P 405550-48-3P 405550-49-4P 405550-50-7P 405550-51-8P
405550-52-9P 405550-53-0P 405550-54-1P 405550-55-2P 405550-56-3P
405550-57-4P 405550-58-5P 405550-59-6P 405550-60-9P 405550-61-0P
405550-62-1P 405550-63-2P 405550-64-3P 405550-65-4P 405550-66-5P
405550-67-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(***farnesyl*** transferase inhibitor; preparation of quinoline and ***quinazoline*** derivs. as ***farnesyl*** transferase inhibitors for treatment of tumors and proliferative diseases)

IT 405548-64-3P, 4-(3-Chlorophenyl)-6-[(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-2-methylquinoline 405548-65-4P, 4-(3-Chlorophenyl)-6-[(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-2-quinolinecarboxylic acid 405548-66-5P, 4-(3-Chlorophenyl)-6-[(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-2-quinolinecarbonyl chloride monohydrochloride 405548-68-7P, (4-Chlorophenyl)[4-(3-chlorophenyl)-2-methyl-6-***quinazolinyl***]methanone 405548-69-8P, 5-[2-(4-Chlorophenyl)-1,3-dioxolan-2-yl]-3-(3-methylphenyl)-2,1-benzisoxazole 405548-70-1P, [2-Amino-5-[2-(4-chlorophenyl)-1,3-dioxolan-2-yl]phenyl](3-methylphenyl)methanone 405548-71-2P, N-[4-[2-(4-Chlorophenyl)-1,3-dioxolan-2-yl]-2-(3-methylbenzoyl)phenyl]acetamide 405548-72-3P, 6-[2-(4-Chlorophenyl)-1,3-dioxolan-2-yl]-4-(3-methylphenyl)-2(1H)-quinolinone 405548-73-4P, 6-(4-Chlorobenzoyl)-4-(3-methylphenyl)-2(1H)-quinolinone 405548-74-5P, [2-Chloro-4-(3-methylphenyl)-6-quinolinyl](4-chlorophenyl)methanone 405548-75-6P, 4-(3-Chlorophenyl)-α-(4-chlorophenyl)-2-hydrazino-α-(1-methyl-1H-imidazol-5-yl)-6-***quinazolinemethanol*** 405548-77-8P, 3-(3-Chlorophenyl)-α-(4-chlorophenyl)-α-(3-pyridinyl)-2,1-benzisoxazole-5-methanol 405548-78-9P, [2-Amino-5-[(4-chlorophenyl)-3-pyridinylmethyl]phenyl](3-chlorophenyl)methanone 405548-79-0P, 4-(3-Chlorophenyl)-6-[(4-chlorophenyl)-3-pyridinylmethyl]-2-methylquinoline 405548-80-3P, 4-(3-Chlorophenyl)-6-[(4-chlorophenyl)-3-pyridinylmethyl]-2-quinolinecarboxaldehyde 405548-94-9P, 4-(3-Chlorophenyl)-α-(4-chlorophenyl)-α-(5-mercapto-4-methyl-4H-1,2,4-***triazol***-3-yl)-2-methyl-6-quinolinemethanol 405548-99-4P, 2-Chloro-α-(4-chlorophenyl)-α-(1-methyl-1H-imidazol-5-yl)-4-(3-methylphenyl)-6-quinolinemethanol
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of quinoline and ***quinazoline*** derivs. as ***farnesyl*** transferase inhibitors for treatment of tumors and proliferative diseases)

IT 131384-38-8, Protein ***farnesyl*** transferase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of quinoline and ***quinazoline*** derivs. as

***farnesyl*** transferase inhibitors for treatment of tumors and proliferative diseases)

IT 67-64-1, 2-Propanone, reactions 98-89-5, Cyclohexanecarboxylic acid 100-36-7 103-71-9, Isocyanato-benzene, reactions 107-11-9, 1-Amino-2-propene 108-00-9, N,N-Dimethyl-1,2-ethanediamine 527-69-5, 2-Furancarbonyl chloride 536-74-3, Ethynylbenzene 586-76-5, 4-Bromobenzoic acid 616-47-7, 1-Methyl-1H-imidazole 626-55-1, 3-Bromopyridine 867-13-0, Ethyl (diethylphosphono)acetate 924-44-7, Oxoacetic acid ethyl ester 1692-25-7, 3-Pyridinylboronic acid 1795-48-8, 2-Isocyanato-propane 2537-48-6, Diethyl (cyanomethyl)phosphonate 2947-60-6, 3-Methylbenzeneacetonitrile 24854-43-1, 4-Methyl-4H-1,2,4-***triazole***-3-thiol 38663-85-3, 1-Isothiocyanato-2-methoxyethane 97674-02-7, Tributyl(1-ethoxyethenyl)stannane 147716-03-8, 1-Methyl-5-(tributylstannyl)-1H-imidazole 190898-64-7, 2-(4-Chlorophenyl)-2-(4-nitrophenyl)-1,3-dioxolane 280143-14-8, 2-Amino-4-(3-chlorophenyl)-α-(4-chlorophenyl)-α-(1-methyl-1H-imidazol-5-yl)-6-quinolinemethanol 280143-17-1, 2-Chloro-4-(3-chlorophenyl)-α-(4-chlorophenyl)-α-(1-methyl-1H-imidazol-5-yl)-6-quinolinemethanol 280143-20-6, 2-Chloro-4-(3-chlorophenyl)-α-(4-chlorophenyl)-α-(1-methyl-1H-imidazol-5-yl)-6-***quinazolinemethanol*** 280143-21-7, 4-(3-Chlorophenyl)-α-(4-chlorophenyl)-2-methyl-α-(1-methyl-1H-imidazol-5-yl)-6-quinolinemethanol 280143-22-8, 4-(3-Chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-2-quinolinecarboxaldehyde 280143-30-8, (4-Chlorophenyl)[4-(3-chlorophenyl)-2-methyl-6-quinolinyl]methanone 405548-67-6, N-[2-(3-Chlorobenzoyl)-4-(4-chlorobenzoyl)phenyl]acetamide 405548-76-7, (4-Chlorophenyl)[3-(3-chlorophenyl)-2,1-benzisoxazol-5-yl]methanone
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of quinoline and ***quinazoline*** derivs. as ***farnesyl*** transferase inhibitors for treatment of tumors and proliferative diseases)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:935605 CAPLUS Full-text
DOCUMENT NUMBER: 136:53760
TITLE: Preparation of (-)-5-(3-chlorophenyl)-α-(4-chlorophenyl)-α-(1-methyl-1H-imidazol-5-yl)tetrazolo[1,5-a]***quinazoline***-7-methanamine as ***farnesyl*** protein transferase inhibitors useful as antitumor agents
INVENTOR(S): Venet, Marc Gaston; ***Angibaud, Patrick Rene***; End, David William
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 16 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2001098302 | A1 | 20011227 | WO 2001-EP6747 | 20010613 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,

LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

| | | | | | |
|---|---|---|---|---|---|
| CA 2410232 | A1 | 20011227 | CA 2001-2410232 | | 20010613 |
| EP 1296984 | A1 | 20030402 | EP 2001-938263 | | 20010613 |
| EP 1296984 | B1 | 20050504 | | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | | |
| BR 2001011743 | A | 20030708 | BR 2001-11743 | | 20010613 |
| HU 200300872 | A2 | 20030728 | HU 2003-872 | | 20010613 |
| JP 2004501153 | T | 20040115 | JP 2002-504258 | | 20010613 |
| EE 200200695 | A | 20040615 | EE 2002-695 | | 20010613 |
| NZ 522481 | A | 20040924 | NZ 2001-522481 | | 20010613 |
| AT 294804 | T | 20050515 | AT 2001-938263 | | 20010613 |
| CZ 295278 | B6 | 20050615 | CZ 2003-114 | | 20010613 |
| ES 2241830 | T3 | 20051101 | ES 2001-1938263 | | 20010613 |
| IN 2002MN01545 | A | 20041211 | IN 2002-MN1545 | | 20021101 |
| BG 107310 | A | 20030731 | BG 2002-107310 | | 20021125 |
| NO 2002006032 | A | 20021216 | NO 2002-6032 | | 20021216 |
| ZA 2002010305 | A | 20040319 | ZA 2002-10305 | | 20021219 |
| US 2003114471 | A1 | 20030619 | US 2002-312301 | | 20021220 |
| HK 1058363 | A1 | 20060210 | HK 2004-101163 | | 20040218 |
| AU 2006220405 | A1 | 20061012 | AU 2006-220405 | | 20060920 |
| PRIORITY APPLN. INFO.: | | | EP 2000-202181 | A | 20000622 |
| | | | AU 2001-263962 | A3 | 20010613 |
| | | | WO 2001-EP6747 | W | 20010613 |

OTHER SOURCE(S): CASREACT 136:53760

AB Title compound, (-)-5-(3-Chlorophenyl)-α-(4-chlorophenyl)-α-(1- methyl-1H-imidazol-5-yl)tetrazolo[1,5-a]***quinazoline*** -7-methanamine and its pharmaceutically acceptable salts, are prepared and formulations useful in medicine are given as ***farnesyl*** protein transferase inhibitors for the treatment of cancer. Thus, the title compound was tested for in vitro assay for inhibition of ***farnesyl*** protein transferase and ***farnesyl*** protein transferase inhibitor secondary tumor model(no data).

IC ICM C07D487-04
ICS A61K031-519; A61P035-00; C07D487-04; C07D257-00; C07D239-00

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63

ST chlorophenyl ***methylimidazolyltetrazoloquinazolinemethanamine***
prepn ***farnesyl*** protein transferase inhibitor; antitumor agent
chlorophenyl ***methylimidazolyltetrazoloquinazolinemethanamine***

IT Antitumor agents
Resolution (separation)
Stereoisomers
(preparation of (-)-5-(3-chlorophenyl)-α-(4-chlorophenyl)-α-(1-methyl-1H-imidazol-5-yl)tetrazolo[1,5-a]***quinazoline*** -7-methanamine as ***farnesyl*** protein transferase inhibitors useful as antitumor agents)

IT 131384-38-8, ***Farnesyl*** transferase
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); NPO (Natural product occurrence); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(preparation of (-)-5-(3-chlorophenyl)-α-(4-chlorophenyl)-α-(1-methyl-1H-imidazol-5-yl)tetrazolo[1,5-a]***quinazoline*** -7-methanamine as ***farnesyl*** protein transferase inhibitors useful as antitumor agents)

IT 382146-82-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (-)-5-(3-chlorophenyl)-α-(4-chlorophenyl)-α-(1-methyl-1H-imidazol-5-yl)tetrazolo[1,5-a]***quinazoline***-7-methanamine as ***farnesyl*** protein transferase inhibitors useful as antitumor agents)

IT 616-47-7, 1-Methylimidazole
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of (-)-5-(3-chlorophenyl)-α-(4-chlorophenyl)-α-(1-methyl-1H-imidazol-5-yl)tetrazolo[1,5-a]***quinazoline***-7-methanamine as ***farnesyl*** protein transferase inhibitors useful as antitumor agents)

IT 215034-82-5P 280143-19-3P 280143-20-6P 280143-59-1P 280144-98-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of (-)-5-(3-chlorophenyl)-α-(4-chlorophenyl)-α-(1-methyl-1H-imidazol-5-yl)tetrazolo[1,5-a]***quinazoline***-7-methanamine as ***farnesyl*** protein transferase inhibitors useful as antitumor agents)

IT 382146-83-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of (-)-5-(3-chlorophenyl)-α-(4-chlorophenyl)-α-(1-methyl-1H-imidazol-5-yl)tetrazolo[1,5-a]***quinazoline***-7-methanamine as ***farnesyl*** protein transferase inhibitors useful as antitumor agents)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:723797 CAPLUS Full-text
DOCUMENT NUMBER: 129:330739
TITLE: ***Farnesyltransferase*** inhibiting ***quinazolinones***
INVENTOR(S): ***Angibaud, Patrick Rene***; Venet, Marc Gaston; Freyne, Eddy Jean Edgard
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 9849157 | A1 | 19981105 | WO 1998-EP2357 | 19980417 |
| W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW | | | | |
| RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| CA 2288140 | A1 | 19981105 | CA 1998-2288140 | 19980417 |
| AU 9876460 | A | 19981124 | AU 1998-76460 | 19980417 |
| AU 738628 | B2 | 20010920 | | |

| | | | | |
|---|---|---|---|---|
| EP 977750 | A1 | 20000209 | EP 1998-924161 | 19980417 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| BR 9809398 | A | 20000613 | BR 1998-9398 | 19980417 |
| TR 9902606 | T2 | 20000721 | TR 1999-2606 | 19980417 |
| NZ 336233 | A | 20010126 | NZ 1998-336233 | 19980417 |
| HU 200001122 | A2 | 20010428 | HU 2000-1122 | 19980417 |
| JP 2001522364 | T | 20011113 | JP 1998-546561 | 19980417 |
| IL 130363 | A | 20020814 | IL 1998-130363 | 19980417 |
| CN 1094937 | B | 20021127 | CN 1998-804366 | 19980417 |
| RU 2205831 | C2 | 20030610 | RU 1999-124815 | 19980417 |
| PL 190944 | B1 | 20060228 | PL 1998-336468 | 19980417 |
| CZ 296959 | B6 | 20060816 | CZ 1999-3717 | 19980417 |
| ZA 9803504 | A | 19991025 | ZA 1998-3504 | 19980424 |
| NO 9905169 | A | 19991227 | NO 1999-5169 | 19991022 |
| NO 317576 | B1 | 20041115 | | |
| MX 9909763 | A | 20000430 | MX 1999-9763 | 19991022 |
| US 6177432 | B1 | 20010123 | US 1999-403705 | 19991022 |
| US 6358961 | B1 | 20020319 | US 2000-687153 | 20001013 |
| US 2002049327 | A1 | 20020425 | US 2000-725391 | 20001129 |
| US 6444812 | B2 | 20020903 | | |

| | | | |
|---|---|---|---|
| PRIORITY APPLN. INFO.: | EP 1997-201259 | A | 19970425 |
| | EP 1997-200708 | A | 19970310 |
| | EP 1997-200709 | A | 19970310 |
| | WO 1998-EP2357 | W | 19980417 |
| | US 1999-403705 | A1 | 19991022 |
| | US 1999-380856 | A3 | 19991220 |

OTHER SOURCE(S): MARPAT 129:330739

GI




I

AB The title compds. I [the dotted line represents an optional bond; X = O, S; R1, R2 = H, hydroxy, halo, cyano, C1-6alkyl, trihalomethyl, trihalomethoxy, C2-6alkenyl, C1-6alkyloxy, hydroxyC1-6alkyloxy, C1-6alkyloxyC1-6alkyloxy, C1-6alkyloxycarbonyl, aminoC1-6alkyloxy, mono- or di(C1-6alkyl)aminoC1-6alkyloxy, Ar1, Ar1C1-6alkyl, Ar1oxy, Ar1C1-6alkyloxy; or when on adjacent positions R1 and R2 taken together may form a bivalent radical; R3, R4 = H, halo, cyano, C1-6alkyl, C1-6alkyloxy, Ar1oxy, C1-6alkylthio, di(C1-6alkyl)amino, trihalomethyl, trihalomethoxy; R5 = H, halo, cyano, optionally substituted C1-6alkyl, C1-6alkyloxycarbonyl, Ar1; or a radical of the formula -OR10, -SR10, -NR11R12; R6 is an optionally substituted imidazolyl moiety; R7 = H, C1-6alkyl provided that the dotted line does not represent a bond; R8 = H, C1-6alkyl or Ar2CH2 or Het1CH2; R9 = H, C1-6alkyl, C1-6alkyloxy, halo, or R8 and R9 taken together may form a bivalent radical; Ar1 and Ar2 are optionally substituted

Ph and Het1 is optionally substituted pyridinyl], having ***farnesyltransferase*** inhibiting activity, were prepared E.g., reaction of 6-[chloro(4-chlorophenyl)methyl]-4-(3-chlorophenyl)-3,4- dihydro-2(1H)-***quinazolinone*** and imidazole gave 44.5% 4-(3-chlorophenyl)-6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3,4-dihydro- 2(1H)-***quinazolinone***.

IC C07D403-06; C07D405-04; A61K031-505; C07D401-14; C07D403-06; C07D239-00; C07D233-00

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1

ST ***quinazolinone*** prepn ***farnesyltransferase*** inhibiting

IT 215034-59-6P 215034-62-1P 215034-65-4P 215034-67-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of ***farnesyltransferase*** inhibiting ***quinazolinones***)

IT 215034-60-9P 215034-61-0P 215034-64-3P 215034-66-5P 215034-68-7P
215034-69-8P 215034-70-1P 215034-71-2P 215034-72-3P 215034-73-4P
215034-75-6P 215034-76-7P 215034-77-8P 215034-78-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of ***farnesyltransferase*** inhibiting ***quinazolinones***)

IT 131384-38-8
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)
(preparation of ***farnesyltransferase*** inhibiting ***quinazolinones***)

IT 288-32-4, 1H-Imidazole, reactions 616-47-7 670-96-2 1529-41-5
1822-51-1 7497-60-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of ***farnesyltransferase*** inhibiting ***quinazolinones***)

IT 190898-64-7P 190898-77-2P 215034-79-0P 215034-80-3P 215034-81-4P
215034-82-5P 215034-83-6P 215034-84-7P 215034-85-8P 215034-86-9P
215034-87-0P 215034-88-1P 215034-89-2P 215034-90-5P 215034-91-6P
215034-92-7P 215034-93-8P 215034-94-9P 215034-95-0P 215034-96-1P
215034-97-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of ***farnesyltransferase*** inhibiting ***quinazolinones***)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file registry
FILE 'REGISTRY' ENTERED AT 15:58:10 ON 14 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.


Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 13 MAR 2007 HIGHEST RN 926304-31-6
DICTIONARY FILE UPDATES: 13 MAR 2007 HIGHEST RN 926304-31-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> file caplus
FILE 'CAPLUS' ENTERED AT 15:58:33 ON 14 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.


FILE COVERS 1907 - 14 Mar 2007 VOL 146 ISS 12
FILE LAST UPDATED: 13 Mar 2007 (20070313/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html
'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> d stat que L7
L3 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation:

Uploading L3.str



ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27 28 29 30 31 32 33 34 35 36 37 39 40 41 42 43 53
ring/chain nodes :
38
chain bonds :
22-23 28-30 36-38 38-39
ring bonds :
1-2 1-5 2-3 3-4 4-5 4-6 5-9 6-7 7-8 7-10 8-13 8-9 10-53 11-14 11-12
13-53 14-15 15-16 15-19 16-17 17-18 18-19 20-21 21-22 23-24 23-27 24-25
25-26 26-27
28-29 30-31 31-32 31-35 32-33 33-34 34-35 36-37 39-40 39-41 40-43 41-42
42-43
exact/norm bonds :
1-2 1-5 2-3 3-4 4-5 4-6 5-9 6-7 7-8 7-10 8-13 8-9 10-53 11-14 11-12
13-53 14-15 15-16 15-19 16-17 17-18 18-19 20-21 21-22 22-23 23-24 23-27
24-25 25-26
26-27 28-29 28-30 30-31 31-32 31-35 32-33 33-34 34-35 36-37 36-38 38-39
39-40 39-41
40-43 41-42 42-43

G1:[*1-*2],[*3-*4],[*5-*6],[*7-*8]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom
22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom
31:Atom 32:Atom

33:Atom  34:Atom  35:Atom  36:Atom  37:Atom  38:Atom  39:Atom  40:Atom  41:Atom
42:Atom  43:Atom
53:Atom

L6           21 SEA FILE=REGISTRY SSS FUL L3
L7            1 SEA FILE=CAPLUS ABB=ON  PLU=ON  L6

=> file beilstein
FILE 'BEILSTEIN' ENTERED AT 15:58:44 ON 14 MAR 2007
COPYRIGHT (c) 2007 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften
licensed to Beilstein GmbH and MDL Information Systems GmbH

FILE LAST UPDATED ON JANUARY 10, 2007

FILE COVERS 1771 TO 2006.
*** FILE CONTAINS  9,780,003 SUBSTANCES ***

>>>PLEASE NOTE: Reaction Data and substance data are stored in
   separate documents and can not be searched together in one query.
   Reaction data for BEILSTEIN compounds may be displayed
   immediately with the display codes PRE (preparations) and REA
   (reactions).  A substance answer set retrieved after the search
   for a chemical name, a compounds with available reaction
   information by combining with PRE/FA, REA/FA or more generally
   with RX/FA. The BEILSTEIN Registry Number (BRN) is the link
   between a BEILSTEIN compound and belonging reactions. For mo
   detailed reaction searches BRNs can be searched as reaction
   partner BRNs Reactant BRN (RX.RBRN) or Product BRN (RX.PBRN).<<<

>>> FOR SEARCHING PREPARATIONS SEE HELP PRE  <<<

**********************************************************************
* PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST.                 *
* SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE    *
* ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE           *
* ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS.                         *
* FOR PRICE INFORMATION SEE HELP COST                                 *
**********************************************************************
    ***NEW***
* ***PATENT NUMBERS (PN) AND BABS ACCESSION NUMBERS (BABSAN) CAN NOW BE***
  ***SEARCHED, SELECTED AND TRANSFERRED.***
* ***NEW DISPLAY FORMATS ALLREF, ALLP AND BABSAN SHOW ALL REFERENCES,***
  ***ALL PATENT REFERENCES, OR ALL BABS ACCESSION NUMBERS FOR A***
  ***COMPOUND AT A GLANCE.***

=> d stat que L9
L3             STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation:
Uploading L3.str



ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27 28 29 30 31 32 33 34 35 36 37 39 40 41 42 43 53
ring/chain nodes :
38
chain bonds :
22-23 28-30 36-38 38-39
ring bonds :
1-2 1-5 2-3 3-4 4-5 4-6 5-9 6-7 7-8 7-10 8-13 8-9 10-53 11-14 11-12
13-53 14-15 15-16 15-19 16-17 17-18 18-19 20-21 21-22 23-24 23-27 24-25
25-26 26-27
28-29 30-31 31-32 31-35 32-33 33-34 34-35 36-37 39-40 39-41 40-43 41-42
42-43
exact/norm bonds :
1-2 1-5 2-3 3-4 4-5 4-6 5-9 6-7 7-8 7-10 8-13 8-9 10-53 11-14 11-12
13-53 14-15 15-16 15-19 16-17 17-18 18-19 20-21 21-22 22-23 23-24 23-27
24-25 25-26
26-27 28-29 28-30 30-31 31-32 31-35 32-33 33-34 34-35 36-37 36-38 38-39
39-40 39-41
40-43 41-42 42-43

G1:[*1-*2],[*3-*4],[*5-*6],[*7-*8]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom
22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom
31:Atom 32:Atom
33:Atom 34:Atom 35:Atom 36:Atom 37:Atom 38:Atom 39:Atom 40:Atom 41:Atom

42:Atom  43:Atom
53:Atom

L9            0 SEA FILE=BEILSTEIN SSS FUL L3

100.0% PROCESSED       5 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.03

=> file marpat
FILE 'MARPAT' ENTERED AT 15:58:53 ON 14 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.


FILE CONTENT: 1961-PRESENT VOL 146 ISS 11 (20070309/ED)

SOME MARPAT RECORDS ARE DERIVED FROM INPI DATA FOR 1961-1987

MOST RECENT CITATIONS FOR PATENTS FROM MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US   2007020715 25 JAN 2007
DE 102005032918 18 JAN 2007
EP      1743897 17 JAN 2007
JP   2007016265 25 JAN 2007
WO   2007012422 01 FEB 2007
GB      2427406 27 DEC 2006
FR      2888248 12 JAN 2007
RU      2291880 20 JAN 2007
CA      2551930 08 JAN 2007

Expanded G-group definition display now available.

=> d stat que L11
L3             STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation:
Uploading L3.str



ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27 28 29 30 31 32 33 34 35 36 37 39 40 41 42 43 53
ring/chain nodes :
38
chain bonds :
22-23 28-30 36-38 38-39
ring bonds :
1-2 1-5 2-3 3-4 4-5 4-6 5-9 6-7 7-8 7-10 8-13 8-9 10-53 11-14 11-12
13-53 14-15 15-16 15-19 16-17 17-18 18-19 20-21 21-22 23-24 23-27 24-25
25-26 26-27
28-29 30-31 31-32 31-35 32-33 33-34 34-35 36-37 39-40 39-41 40-43 41-42
42-43
exact/norm bonds :
1-2 1-5 2-3 3-4 4-5 4-6 5-9 6-7 7-8 7-10 8-13 8-9 10-53 11-14 11-12
13-53 14-15 15-16 15-19 16-17 17-18 18-19 20-21 21-22 22-23 23-24 23-27
24-25 25-26
26-27 28-29 28-30 30-31 31-32 31-35 32-33 33-34 34-35 36-37 36-38 38-39
39-40 39-41
40-43 41-42 42-43

G1:[*1-*2],[*3-*4],[*5-*6],[*7-*8]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom
22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom
31:Atom 32:Atom
33:Atom 34:Atom 35:Atom 36:Atom 37:Atom 38:Atom 39:Atom 40:Atom 41:Atom

42:Atom  43:Atom
53:Atom

L11  1 SEA FILE=MARPAT SSS FUL L3

100.0% PROCESSED  299 ITERATIONS  1 ANSWERS
SEARCH TIME: 00.00.01

=> dup rem L7 L9 L11
L9 HAS NO ANSWERS
DUPLICATE IS NOT AVAILABLE IN 'BEILSTEIN'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
FILE 'CAPLUS' ENTERED AT 15:59:32 ON 14 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MARPAT' ENTERED AT 15:59:32 ON 14 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)
PROCESSING COMPLETED FOR L7
PROCESSING COMPLETED FOR L9
PROCESSING COMPLETED FOR L11
L27  1 DUP REM L7 L9 L11 (1 DUPLICATE REMOVED)
  ANSWER '1' FROM FILE CAPLUS

=> d ibib abs hitstr L27 1

L27  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2007 ACS on STN  DUPLICATE 1
ACCESSION NUMBER:  2003:837087  CAPLUS  Full-text
DOCUMENT NUMBER:  139:337983
TITLE:  Preparation of farnesyl transferase inhibiting tetrazoloquinazolines substituted with carbon-linked imidazoles or triazoles
INVENTOR(S):  Angibaud, Patrick Rene; Venet, Marc Gaston; Argoullon, Jean Michel Jacques Raymond
PATENT ASSIGNEE(S):  Janssen Pharmaceutica N.V., Belg.
SOURCE:  PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DOCUMENT TYPE:  Patent
LANGUAGE:  English
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2003087101 | A1 | 20031023 | WO 2003-EP3986 | 20030414 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,

KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

| | | | | |
|---|---|---|---|---|
| CA 2481480 | A1 | 20031023 | CA 2003-2481480 | 20030414 |
| AU 2003229688 | A1 | 20031027 | AU 2003-229688 | 20030414 |
| EP 1497295 | A1 | 20050119 | EP 2003-722496 | 20030414 |
| EP 1497295 | B1 | 20060816 | | |

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

| | | | | |
|---|---|---|---|---|
| US 2005148609 | A1 | 20050707 | US 2003-509365 | 20030414 |
| JP 2005526109 | T | 20050902 | JP 2003-584057 | 20030414 |
| AT 336496 | T | 20060915 | AT 2003-722496 | 20030414 |
| PRIORITY APPLN. INFO.: | | | EP 2002-76448 A | 20020415 |
| | | | WO 2003-EP3986 W | 20030414 |

OTHER SOURCE(S): MARPAT 139:337983

GI



I



II

AB Title compds. I [R1, R2 = (un)substituted Ph; R3 = H, halogen, CN, (un)substituted alkyl, alkenyl, alkynyl, CO2H, aryl, heterocyclic, OH, SH, NH2, N:CH2; R4 = (un)substituted imidazol-5-yl, 4H-1,2,4-triazol-3-yl; R5 = CN, OH, halogen, (un)substituted alkyl, alkenyl, alkynyl, alkoxy, CO2H, NH2, CONH2; R6 = H, (un)substituted alkyl; n = 0-2] were prepared for use as farnesyl transferase inhibitors in the treatment of proliferative diseases. Thus, the title compound I was prepared by rearrangement of 5-(3-chlorophenyl)-α-(4-chlorophenyl)-4,5-dihydro-α-(1-methyl- 1H-imidazol-5-yl)tetrazolo[1,5-a]quinazolinemethanol and gave 81% inhibition of farnesyl transferase at 1X10-7 M.

IT ***615277-93-5P 615277-99-1P 615278-09-6P 615278-39-2P 615278-42-7P***

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of farnesyl transferase inhibiting tetrazoloquinazolines substituted with carbon-linked imidazoles or triazoles)

RN 615277-93-5 CAPLUS

CN Tetrazolo[5,1-b]quinazoline-7-methanol, 9-(3-chlorophenyl)-α-(4-

chlorophenyl)-1,9-dihydro-α-(1-methyl-1H-imidazol-5-yl)- (9CI) (CA INDEX NAME)



RN 615277-99-1 CAPLUS
CN Tetrazolo[5,1-b]quinazoline-7-methanol, 9-(3-chlorophenyl)-1,9-dihydro-α-(4-methoxyphenyl)-α-(1-methyl-1H-imidazol-5-yl)- (9CI) (CA INDEX NAME)



RN 615278-09-6 CAPLUS
CN Tetrazolo[5,1-b]quinazoline-7-methanol, 9-(3-chlorophenyl)-1,9-dihydro-α-(4-methoxyphenyl)-α-(1-methyl-1H-imidazol-5-yl)-, (αR,9R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 615278-39-2 CAPLUS
CN Tetrazolo[5,1-b]quinazoline-7-methanol, 9-(3-chlorophenyl)-1,9-dihydro-

α-(4-iodophenyl)-α-(1-methyl-1H-imidazol-5-yl)- (9CI) (CA INDEX NAME)



RN 615278-42-7 CAPLUS

CN Tetrazolo[5,1-b]quinazoline-7-methanol, 9-(3-chlorophenyl)-4,9-dihydro-α-(4-iodophenyl)-4-methyl-α-(1-methyl-1H-imidazol-5-yl)- (9CI) (CA INDEX NAME)



IT ***615277-96-8P 615278-01-8P 615278-03-0P 615278-06-3P 615278-12-1P 615278-15-4P 615278-18-7P 615278-21-2P 615278-24-5P 615278-27-8P 615278-30-3P 615278-40-5P 615278-41-6P 615278-44-9P 615278-45-0P 615278-47-2P***

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of farnesyl transferase inhibiting tetrazoloquinazolines substituted with carbon-linked imidazoles or triazoles)

RN 615277-96-8 CAPLUS

CN Tetrazolo[5,1-b]quinazoline-7-methanol, 9-(3-chlorophenyl)-α-(4-fluorophenyl)-1,9-dihydro-α-(1-methyl-1H-imidazol-5-yl)- (9CI) (CA INDEX NAME)




RN 615278-01-8 CAPLUS
CN Tetrazolo[5,1-b]quinazoline-7-methanamine, 9-(3-chlorophenyl)-1,9-dihydro-α-(1-methyl-1H-imidazol-5-yl)-α-(4-methylphenyl)-, (αR,9R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 615278-03-0 CAPLUS
CN Tetrazolo[5,1-b]quinazoline-7-methanamine, 9-(3-chlorophenyl)-1,9-dihydro-α-(1-methyl-1H-imidazol-5-yl)-α-(4-methylphenyl)-, (αR,9S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 615278-06-3 CAPLUS
CN Tetrazolo[5,1-b]quinazoline-7-methanol, 9-(3-chlorophenyl)-4,9-dihydro-α-(4-methoxyphenyl)-4-methyl-α-(1-methyl-1H-imidazol-5-yl)-

(9CI) (CA INDEX NAME)




RN 615278-12-1 CAPLUS
CN Tetrazolo[5,1-b]quinazoline-7-methanol, 9-(3-chlorophenyl)-1,9-dihydro-α-(4-methoxyphenyl)-α-(1-methyl-1H-imidazol-5-yl)-, (αS,9R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 615278-15-4 CAPLUS
CN Tetrazolo[5,1-b]quinazoline-7-methanol, 9-(3-chlorophenyl)-4-(cyclopropylmethyl)-4,9-dihydro-α-(4-methoxyphenyl)-α-(1-methyl-1H-imidazol-5-yl)- (9CI) (CA INDEX NAME)



RN 615278-18-7 CAPLUS
CN Tetrazolo[5,1-b]quinazoline, 9-(3-chlorophenyl)-7-[(4-chlorophenyl)ethoxy(1-methyl-1H-imidazol-5-yl)methyl]-1,9-dihydro- (9CI) (CA INDEX NAME)




RN 615278-21-2 CAPLUS
CN Tetrazolo[5,1-b]quinazoline-7-methanamine, 9-(3-chlorophenyl)-α-(4-chlorophenyl)-1,9-dihydro-α-(1-methyl-1H-imidazol-5-yl)-, (αR,9S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 615278-24-5 CAPLUS
CN Tetrazolo[5,1-b]quinazoline-7-methanamine, 9-(3-chlorophenyl)-α-(4-chlorophenyl)-1,9-dihydro-α-(1-methyl-1H-imidazol-5-yl)-, (αR,9R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 615278-27-8 CAPLUS
CN Tetrazolo[5,1-b]quinazoline-4(9H)-acetic acid, 9-(3-chlorophenyl)-7-[hydroxy(4-methoxyphenyl)(1-methyl-1H-imidazol-5-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 615278-30-3 CAPLUS
CN Benzonitrile, 4-[[9-(3-chlorophenyl)-7-[hydroxy(4-methoxyphenyl)(1-methyl-1H-imidazol-5-yl)methyl]tetrazolo[5,1-b]quinazolin-4(9H)-yl]methyl]- (9CI) (CA INDEX NAME)




RN 615278-40-5 CAPLUS

CN Tetrazolo[5,1-b]quinazoline-7-methanol, 9-(3-chlorophenyl)-α-(4-chlorophenyl)-4,9-dihydro-4-methyl-α-(1-methyl-1H-imidazol-5-yl)- (9CI) (CA INDEX NAME)



RN 615278-41-6 CAPLUS
CN Tetrazolo[5,1-b]quinazoline, 9-(3-chlorophenyl)-4,9-dihydro-7-[(4-methoxyphenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 615278-44-9 CAPLUS
CN Tetrazolo[5,1-b]quinazoline-7-methanamine, 9-(3-chlorophenyl)-α-(4-chlorophenyl)-1,9-dihydro-α-(1-methyl-1H-imidazol-5-yl)-, (αR,9R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 615278-45-0 CAPLUS
CN Tetrazolo[5,1-b]quinazoline-7-methanamine, 9-(3-chlorophenyl)-α-(4-chlorophenyl)-1,9-dihydro-α-(1-methyl-1H-imidazol-5-yl)-, (αS,9R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 615278-47-2 CAPLUS
CN Benzoic acid, 4-[[9-(3-chlorophenyl)-4,9-dihydro-4-methyltetrazolo[5,1-b]quinazolin-7-yl]hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d his full

     (FILE 'HOME' ENTERED AT 15:21:25 ON 14 MAR 2007)

     FILE 'REGISTRY' ENTERED AT 15:21:48 ON 14 MAR 2007
L1                STRUCTURE UPLOADED
                  D L1
L2              2 SEA SSS SAM L1
                  D SCA

     FILE 'STNGUIDE' ENTERED AT 15:29:12 ON 14 MAR 2007

     FILE 'REGISTRY' ENTERED AT 15:39:44 ON 14 MAR 2007
L3                STRUCTURE UPLOADED
L4              2 SEA SSS SAM L3
                  D SCA
L5              2 SEA ABB=ON  PLU=ON  L4 AND L2
                  D STAT QUE L4
L6             21 SEA SSS FUL L3
                  SAVE TEMP L6 WAR365STR3L/A
                  D SCA

     FILE 'CAPLUS' ENTERED AT 15:42:29 ON 14 MAR 2007
L7              1 SEA ABB=ON  PLU=ON  L6

     FILE 'BEILSTEIN' ENTERED AT 15:42:39 ON 14 MAR 2007
L8              0 SEA SSS SAM L3
L9              0 SEA SSS FUL L3

     FILE 'MARPAT' ENTERED AT 15:43:24 ON 14 MAR 2007
L10             0 SEA SSS SAM L3
L11             1 SEA SSS FUL L3
                  D SCA
                  D COST

     FILE 'REGISTRY' ENTERED AT 15:45:47 ON 14 MAR 2007
                  D RSD L6 1
L12           197 SEA ABB=ON  PLU=ON  1894.286/RID

     FILE 'CAPLUS' ENTERED AT 15:47:26 ON 14 MAR 2007
L13            15 SEA ABB=ON  PLU=ON  L12

     FILE 'REGISTRY' ENTERED AT 15:49:21 ON 14 MAR 2007
L*** DEL        0 S N4C-NCNC3-C6/ESS

     FILE 'CAPLUS' ENTERED AT 15:50:17 ON 14 MAR 2007
                  E ANGIBAUD/AU
L14            43 SEA ABB=ON  PLU=ON  ANGIBAUD P?/AU
L15             1 SEA ABB=ON  PLU=ON  L13 AND L14
L16          7835 SEA ABB=ON  PLU=ON  ?FARNESYL?/BI
L17            23 SEA ABB=ON  PLU=ON  L14 AND L16
L18         15726 SEA ABB=ON  PLU=ON  ?QUINAZOLIN?/BI
L19            11 SEA ABB=ON  PLU=ON  L14 AND L18
L20         69395 SEA ABB=ON  PLU=ON  ?TRIAZOL?/BI
L21            12 SEA ABB=ON  PLU=ON  L14 AND L20
L22         69400 SEA ABB=ON  PLU=ON  L19 OR L20
L23            17 SEA ABB=ON  PLU=ON  L19 OR L21
L24            15 SEA ABB=ON  PLU=ON  L23 AND L16
```

```
L25          17 SEA ABB=ON  PLU=ON  (L23 OR L24)
L26           1 SEA ABB=ON  PLU=ON  L25 AND L7

     FILE 'REGISTRY' ENTERED AT 15:55:16 ON 14 MAR 2007

     FILE 'CAPLUS' ENTERED AT 15:55:19 ON 14 MAR 2007
               D STAT QUE L25
               D IBIB ABS HITIND L25 1-17

     FILE 'REGISTRY' ENTERED AT 15:58:10 ON 14 MAR 2007

     FILE 'CAPLUS' ENTERED AT 15:58:33 ON 14 MAR 2007
               D STAT QUE L7

     FILE 'BEILSTEIN' ENTERED AT 15:58:44 ON 14 MAR 2007
               D STAT QUE L9

     FILE 'MARPAT' ENTERED AT 15:58:53 ON 14 MAR 2007
               D STAT QUE L11

     FILE 'CAPLUS, MARPAT' ENTERED AT 15:59:32 ON 14 MAR 2007
L27           1 DUP REM L7 L9 L11 (1 DUPLICATE REMOVED)
                    ANSWER '1' FROM FILE CAPLUS
               D IBIB ABS HITSTR L27 1


     FILE HOME

     FILE REGISTRY
     Property values tagged with IC are from the ZIC/VINITI data file
     provided by InfoChem.

     STRUCTURE FILE UPDATES:   13 MAR 2007  HIGHEST RN 926304-31-6
     DICTIONARY FILE UPDATES:  13 MAR 2007  HIGHEST RN 926304-31-6

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

     TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

       Please note that search-term pricing does apply when
       conducting SmartSELECT searches.

     REGISTRY includes numerically searchable data for experimental and
     predicted properties as well as tags indicating availability of
     experimental property data in the original document.  For information
     on property searching in REGISTRY, refer to:

     http://www.cas.org/ONLINE/UG/regprops.html

     FILE STNGUIDE
     FILE CONTAINS CURRENT INFORMATION.
     LAST RELOADED: Mar  9, 2007 (20070309/UP).

     FILE CAPLUS

     Copyright of the articles to which records in this database refer is
     held by the publishers listed in the PUBLISHER (PB) field (available
     for records published or updated in Chemical Abstracts after December
     26, 1996), unless otherwise indicated in the original publications.
     The CA Lexicon is the copyrighted intellectual property of the
```

FILE COVERS 1907 - 14 Mar 2007 VOL 146 ISS 12
FILE LAST UPDATED: 13 Mar 2007 (20070313/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

FILE BEILSTEIN
FILE LAST UPDATED ON JANUARY 10, 2007

FILE COVERS 1771 TO 2006.
***FILE CONTAINS 9,780,003 SUBSTANCES***

>>>PLEASE NOTE: Reaction Data and substance data are stored in separate documents and can not be searched together in one query. Reaction data for BEILSTEIN compounds may be displayed immediately with the display codes PRE (preparations) and REA (reactions). A substance answer set retrieved after the search for a chemical name, a compounds with available reaction information by combining with PRE/FA, REA/FA or more generally with RX/FA. The BEILSTEIN Registry Number (BRN) is the link between a BEILSTEIN compound and belonging reactions. For mo detailed reaction searches BRNs can be searched as reaction partner BRNs Reactant BRN (RX.RBRN) or Product BRN (RX.PBRN).<<<

>>> FOR SEARCHING PREPARATIONS SEE HELP PRE <<<

**********
* PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST. *
* SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE *
* ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE *
* ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS. *
* FOR PRICE INFORMATION SEE HELP COST *
**********

***NEW***

* ***PATENT NUMBERS (PN) AND BABS ACCESSION NUMBERS (BABSAN) CAN NOW BE SEARCHED, SELECTED AND TRANSFERRED.***
* ***NEW DISPLAY FORMATS ALLREF, ALLP AND BABSAN SHOW ALL REFERENCES, ALL PATENT REFERENCES, OR ALL BABS ACCESSION NUMBERS FOR A COMPOUND AT A GLANCE.***

FILE MARPAT
FILE CONTENT: 1961-PRESENT VOL 146 ISS 11 (20070309/ED)

SOME MARPAT RECORDS ARE DERIVED FROM INPI DATA FOR 1961-1987

MOST RECENT CITATIONS FOR PATENTS FROM MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US 2007020715 25 JAN 2007
DE 102005032918 18 JAN 2007
EP 1743897 17 JAN 2007
JP 2007016265 25 JAN 2007
WO 2007012422 01 FEB 2007

```
GB      2427406 27 DEC 2006
FR      2888248 12 JAN 2007
RU      2291880 20 JAN 2007
CA      2551930 08 JAN 2007

Expanded G-group definition display now available.

=>
```